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ABSTRACT 
The Thesis entitled "Vector screening, relapse and resistance 
patterns of malaria in Aligarh" comprises of 3 chapters. First chapter is 
regarding screening and incrimination of malaria vector. Second pertains 
to relapse and resistance patterns of Plasmodium vivax and Plasmodium 
falciparum against chloroquine. While third chapter is about resistance in 
P. falciparum and P. vivax involving DHFR mutation against 
pyrimethamine-sulfadoxine combination which is generally used in 
resistant falciparum cases. 
For vector screening mosquitoes were collected from different 
localities of Aligarh, in the early morning and evening from cattle shed and 
human dwellings. Mosquitoes were anaesthetized with ether and identified 
on the basis of morphological features with the help of standard regional 
pictorial key of Wattal and Kaira (1961). For vector incrimination three 
suspected species viz. An. culicifacies, An. Stephens! and An. annularis, 
collected from human dwellings during high transmission season were 
dissected to look for the salivary gland and gut infection. Sprozoite positive 
slides were stained with Leishman's stain. For human blood index, blood 
smears were prepared from the gut of fully fed female anophelines on 
Whatman filter paper no.1 and analysed by counter current 
electrophoresis. 
Survey for the screening of anopheline mosquito was carried out 
from December, 2000 to November, 2002 in Aligarh revealed the presence 
of seven species i.e. An. culicifacies, An. subpictus, An. annularis, An. 
Stephens}, An. vagus, An. barbirosths, and An. lindesayi. An. culicafacies 
was the predominant species (37.02%) in the area followed by An. 
subpictus (35.01%), An. annularis (16.07%), An. stephensi (8.78%) and 
An. vagus (2.68 %). Whereas rest of the anopheline species i.e. An. 
barbirosths (0.22%) and An. lindesayi (0.21%) were recorded less than 
one percent in Aligarh. o t m l S 
Most of the anophelines were quite abundant during post monsoon 
season (i.e. from July to November). During these months moderate 
temperature (26-28°C) and optimum humidity (77-88%) prevailed which 
were ideal for breeding of mosquitoes and accounted for increase in 
mosquito density. An. culicifacies and An. stepiiensi showed liking for 
human blood. Human blood index for the aforesaid species were 37.80% 
and 39.5%, respectively. An. culicifacies and An. steptiensi were found 
positive for sporozoites. Sporozoite positivity rates recorded for An. 
culicifacies and An. stephensi \Nere 0.41% and 0.26%, respectively. 
Thin and thick blood smears of the suspected malaria patients were 
prepared by finger prick and stained with J.S.B. and Giemsa stain, and 
examined microscopically for the positivity of malaria infection. For the 
study of relapse and resistance, patients were treated with standard dose 
of chloroquine according to the National drug Policy of India and followed 
up carefully. Seasonal correlation of these infections was also studied. 
Relapse and resistance rates were determined in Plasmodium vivax and 
Plasmodium falciparum infections during 2001, 2002 and 2003. Relapse 
rates were 15.2%, 19.1% and 17.1% while resistance rates were 9.6%, 
10.8% and 11.4%, respectively. Peak transmission of malaria with a slide 
positivity rate 61.76 to 50.14%, was recorded during September and 
October which happens to be the peak transmission months. Lowest 
transmission was recorded during March and April when slide falciparum 
rate was minimum (5.12%-9.25%). 88 patients who were administered 
with 1500 mg chloroquine and 75 mg primaquine in divided doses also 
showed relapse rate of 4.5%. Short term relapses were more then the long 
term relapses in the ratio of about 4:1.Three chloroquine resistant cases of 
Plasmodium vivax were also recorded in the present study. Patients 
suffering from falciparum malaria showed resistance against chloroquine in 
9.6, 10.8 and 11.4% cases after getting 1500 mg chloroquine base in 
divided doses (i.e. 600 mg on day 0, 300 mg after 8 hours followed by 300 
mg daily for 2 days). Level of resistance in these cases was of R I and Rll 
type. 
For pyrimethamine resistance associated mutations in Plasmodium 
vivax and Plasmodium falciparum thick and thin blood smears of the 
patients were stained and screened by light microscopy. 100-200 \J\ of 
heparinized blood was collected from malaria positive patients. Parasite 
DNA was extracted from the blood of P. vivax and P. falciparum patients 
using Accu Prep Genomic DNA extraction kit (Bioneer Corporation, 
Korea). The DNA was eluted in Tris-EDTA buffer (pH 8.0), and an aliquot 
was used for the PCR amplification A 1,014-bp fragment of P. vivax dhfr-
ts gene was amplified using primers PvDA (5'- ACCGCACCAGTTCCTAC-
3') (forward) andPvDB(5'- TGTTAAAGCTGAAGTACACGAG-3') (reverse) 
with different cycling parameters. The primary PCR product was diluted 10 
times and used as a DNA template for nested PCR to amplify the 784-bp 
region which covers the entire DHFR domain Primers PvDF (5'-
ATGGAGGACCTTTCAGATGT-3') (forward) and PvDR (5'-
AACGCATTGCAGTTCTCCGA-3') (reverse) were used for nested PCR 
with the different cycling parameters. For nucleotide sequencing an 
individual band of each PCR product was purified using an Accu Prep gel 
purification l^ it (Bioneer corporation, Korea).The entire pvdtifr gene was 
sequenced using primers PvDM (5'- GTTAGCGTCTTGGAAAGCAC-3') 
and PvDR. For P. falciparum, DNA was extracted and subjected to PCR 
amplification of a 720-bp fragment of the pfdhfr gene by using primers 
AMP-1(5"-TTTATATTTTCTCCTTTTTA-3') and AMP-2(5'-
CATTTTATTATTCGTTTTCT-3'). An aliquot of the primary amplificon was 
diluted and subjected to the seminested PCR using primers AMP1 and 
DHFRR2 (5' ACAGAAATAATTTGATACTCA-3'). The PCR products were 
purified and subjected to nucleotide sequencing using an ABI big dye 
terminator ready reaction kit, version 3.1 and ABI prism 310 genetic 
analyzer (PE Applied Biosystems, California). The nucleotide sequences 
were translated into amino acids using the Edit sequence programme 
(Lasergene, version 5.1 July, 1999; DNASTAR Inc., Madison, Wl). Amino 
acid sequences were aligned using the Gene Doc Multiple Sequence 
Alignment Editor and Shading Utility (Version 2.6.002). 
Nucleotide sequencing result of DHFR domain of P. falciparum isolates 
showed double mutations in PFDHFR in 64.09% cases, while single 
mutation was observed in only 33.33% cases in Aligarh. The genotypes in 
P. falciparum having double mutation were A16N51R59N108I164-
A16I51C59N108I164 and A16N51C59N108L164. while those having single mutation 
were AieNsiCsgNioslieg- Wild type which constituted only 2.56% having 
genotype A16N51C59S108I164. 
In case of P. vivax majority of isolates (57.98%) contained wild type 
of amino acids in DHFR. However, frequencies of double and single 
mutations in PVDHFR were 34.21% and 7.89%, respectively. Majority of 
the isolates with mutated genotype contained only three GGDN repeats, 
while wild type PVDHFR genotype had variable number of GGDN repeats. 
Among isolates of P. vivax wild type of amino acids at the 5 codons of 
PVDHFR were F57S58T61S93S117 Genotypes showing single mutation were 
FszSssTeiSgaNiir and F57S58T61H93S117, while genotype showing double 
mutations was FsyRssTeiSgsNii?-
In our experimental area pyrimethamine and sulfadoxine 
combination was used as alternative treatment for resistant P. falciparum 
and also in normal cases without confirmation of specific diagnosis. This 
tendency increased the drug pressure on both P. vivax and P. falciparum, 
as they co-exist. Both these parasites got affected as they have common 
drug target (DHFR). This led to the gene mutations in PFDHFR and 
PVDHFR. Although similar DHFR mutation patterns were observed, there 
was a significant difference in the rate of DHFR between P. vivax and P. 
falciparum. The overall DHFR mutation rate for P. vivax was significantly 
lower than that of P. falciparum. Considering the fact that pyrimethamine-
sulfadoxine Is used for P. falciparum malaria treatment and not for P. 
vivax. The latter parasite expectedly showed the lower rate of DHFR 
mutations. It is estimated that the useful therapeutic life (UTL) of 
pyrimethamine-sulfadoxine combination, showing enhanced inhibitory 
antifolate activity is only 5 years. If its indiscriminate and uncontrolled use 
could not be checked it may result in further more mutations and drug 
resistance, as this drug combination is retained in the body of the patient 
for longer duration because of its longer half life. 
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Introduction 
INTRODUCTION 
PART A Vector Screening and Incrimination 
Malaria, one of the six diseases included in WHO special 
programme, is causing a lot of morbidity and mortality all around the world. 
Malaria is prevalent in humid tropics between latitude 45° N and 45°S 
mainly in Africa, Asia and Central and South America. Over 40% 
population of world is exposed to the risk of malaria. Malaria is a major 
burden for the most resource-poor nations of the world. At present about 
100 countries in the world are considered malarious. Between 200 and 500 
millions cases of malaria occur annually with an estimated 1.7-3 million 
deaths attributable to malaria, most among the children of Sub-Saharan 
Africa (Breman, 2001). In fact, 9 out of 10 cases of malaria occur in this 
region, while two third of rest are concentrated in just six countries viz., 
India, Brazil, Sri Lanka, Vietnam, Cambodia and Solomon Island. Every 
year malaria kills 1.5 to 2.5 million people mostly children of below 5 years 
age (Kondrachine and Trigg, 1997). The goal of eradicating malaria, once 
thought to be possible, was abandoned decades ago, and the present goal 
of malaria control is first to retard the accelerating rates of disease and 
death and then to "Roll Back Malaria". 
Historically, malaria has been a problem in India for centuries. 
Malaria is endemic in India with varying levels of endemicity. Most regions 
in the country have an unstable malaria situation except in the North-
Eastern region where stable malaria situation prevails. There are many 
endemic pockets of malaria in India particularly in North Eastern States, 
Orissa, West Bengal and Madhya Pradesh. Situation of malaria in India till 
1950's was very serious, with over 75 million cases and 0.8 million deaths 
every year. Keeping grave situation of malaria in view, National Malaria 
Control Programme (NMCP) was started in 1953 and encouraging results 
were obtained. Later on after 5 years National Malaria Eradication 
Programme (NMEP) was launched in 1958, which resulted in dramatic 
decrease in malaria cases. In 1965 cases came down to 0.1 million with no 
death record. Euphoria of success was so overwhelming that malaria was 
considered as a disease of past. Resurgence of malaria occurred in 1970 
because of administrative, financial and technical failure (Sharma and 
Mehrotra, 1986). The implementation of urban malaria scheme (UMS) in 
1971-72 and the modified plan of operation (MPO) in 1977 improved the 
malaria situation for 5-6 years. Malaha cases were reduced to about 2 
million. The impact was mainly on vivax malaria. Easy availability of drugs 
under the MPO prevented deaths due to malaria and reduced morbidity, a 
peculiar feature of malaria during resurgence. The Plasmodium falciparum 
containment programme (PfCP) was launched in 1977 to reduce 
falciparum malaria in the selected areas but its general spread could not 
be contained. Plasmodium falciparum showed a steady upward trend 
during the 1970s and thereafter. Malaria at one time considered a rural 
disease, later on diversified into various ecotypes. These ecotypes have 
been identified as forest malaria, urban malaria, rural malaria, industrial 
malaria, border malaria and migration malaria; the latter cutting across 
boundaries of various epidemiological types. In 1990s malaria re-emerged 
and took the lives of several thousand people (Sharma, 1996). Factors 
responsible for the re-emergence of malaria were vector resistance to 
insecticide and parasite's resistance to drug. 
Anopheles mosquitoes are most frequent in tropical and sub tropical 
regions. There are about 420 species of Anopheles in the world and out of 
these 70 are well-known malaria vectors. Anopheles mosquitoes are found 
in all parts of India from the sea level upto an altitude of 3,530 meters. In 
peninsular India and eastern India where temperatures are moderate, 
Anopheles prevailed throughout the year. In India 58 species of Anopheles 
are recorded, out of which six are considered as primary vectors and four 
as secondary vectors. The primary vectors include An. culicifacies, An. 
Stephens!, An. fluviatilis, An. dims, An. minimus and An. sundaicus 
whereas An. annularis, An. philippiensis (nivipes). An. varuna and An. 
jeypoiiensis are considered as secondary vectors (Rao, 1984) (Mapl). 
Among the primary vectors An. culicifacies has been established as a 
major vector of malaria in rural and periurban areas of India (Subbarao et 
al. 1988). An. culicifacies is responsible for 60-70% of total malaria cases 
reported annually in India (Sharma, 1984). 
In Aligarh, where the proposed work is carried out is situated in the 
upper Ganga-Yamuna Doab and occupies the northern most portion of 
Agra division. It extends from 27° 29' N to 28° 11' N latitudes and 77° 29' to 
78° 38' longitudes. It has tropical monsoon type of climate with its highly 
attributed seasonal variations including the North-East and North-West 
monsoons. The North-East monsoon occurs from December to mid June 
and is distinguished by high temperature and dry winds of continental 
region. Clear skies, dust and low humidity are observed from time to time. 
While rest of the period, that is from mid June to October is marked by 
humid winds of oceanic origin, including cloudy weather, rainfall and high 
relative humidity. Aligarh experiences extreme cold during winter as there 
is a subsequent fall in temperature. The average maximum temperature in 
November is 29.5°C while in January which is the coldest month of the 
year, the mean maximum and minimum temperatures being 20°C and 4°C, 
respectively. The hot weather starts from March and continues till June, is 
marked by a noticeable rise in maximum and minimum temperatures in 
March being 34.9°C and 15.6°C, respectively. The temperature then 
continues to rise considerably in May and June. The maximum 
temperature rises to 38.7°C in May and 39.6°C in June. 
The onset and retreat time of the monsoon differs considerably 
every year. Usually the rain starts by the mid of June and continues till the 
end of September or early October. During this period of the year 90% of 
the total annual precipitation occurs. Excess rain in this part of the year 
may cause the low-lying areas or depressions and ditches to be water-
logged. Relative humidity varies considerably throughout the year. With the 
onset of monsoon, the relative humidity increases ranging from 65% to 
77%. January records the highest percentage of relative humidity about 
82%. While during the summer season, particularly in May relative 
humidity is lowest i.e. about 41%. 
In the experimental area a variety of mosquito breeding grounds are 
present which facilitates the emergence of different anopheline species. 
Although enough literature is available on mosquito fauna and vectors from 
many parts of India but published information on screening and vector 
incrimination of malaria in Aligarh is not available. The present study was, 
therefore, undertaken to screen and incriminate the malaria vector in 
Aligarh. Sporozolte positivity rate and human blood index were also 
recorded for the vector species as they have direct bearing in malaria 
transmission. 
PART B Relapse and Resistance patterns in P. vivax and P. 
falciparum 
More than 100 Plasmodium species have been described causing 
malaria in a wide range of vertebrates and exhibiting narrowly defined 
host-specificity (Garnham, 1980). Among 100 species, only four infect men 
which are Plasmodium vivax, Plasmodium falciparum, Plasmodium 
malariae and Plasmodium ovale. In India Plasmodium vivax and 
Plasmodium falciparum causes benign and malignant tertian malaria. In 
India 60-65% of the malaria infections are reported to be due to 
Plasmodium vivax and 30-35% due to Plasmodium falciparum (Adak et al. 
1998). Of all species of human Plasmodia, Plasmodium falciparum is 
highly pathogenic causing malignant tertian malaria with high rate of 
morbidity and mortality. This parasite shows resistance against routine 
curative drugs such as chloroquine, amodiaquine, metakelfin, fansidar and 
mefloquine in endemic areas thus posing serious problems in cure of this 
disease. 
The worsening problems of drug resistance in many parts of the 
world and the limited number of antimalarial drugs available has increased 
difficulties for the development of antimalarial drug policies and the 
provision of adequate disease management. It is now recognized that most 
endemic countries will have to face the unavoidability of some resistance 
to the antimalarial drugs used to treat uncomplicated malaria. 
The strain of Plasmodium falciparum resistant to the antimalarials 
spread from areas with massive population movements, inadequate health 
services, improper use of antimalarial drugs and limited resources and 
operational difficulties in implementing malaria control activities. 
Chloroquine resistance arose on the Thai-Cambodian border and in 
Amazonia in the early 1960s, first being observed in non-immune migrants 
into hyper endemic malaria areas. It spread to Africa in the 1970s, being 
first reported in East Africa, again in non-immune patients and later being 
confirmed among the local population. Chloroquine resistance now 
common in practically all endemic countries of Africa, especially in East 
Africa which poses increasing problems for the provision of adequate 
treatment. Resistance to main alternative of chloroquine, 
sulfadoxine/pyrimethamine is wide spread in South-East Asia and South 
America but it is focal in other parts of the world. Mefloquine resistance is 
now common in the border areas of Thailand with Cambodia and Myanmar 
and the sensitivity to quinine is declining in several countries of South-East 
Asia and in Brazil where it has been used in uncomplicated malaria. 
Consequently, artemisine and its derivates are now increasingly being 
used as first line of treatment in some of these areas (WHO, 1993). 
It is not surprising that the malaria parasite, in response to an 
increasing use of antimalarial drugs, has found its natural defence in the 
development of resistance. In India resistance of Plasmodium falciparum 
\ l^^ " " 7 
to chloroquine, the cheapest and the most frequently used therapeutic 
drug was first reported in the year 1973 from Diphu of Karbi-Analog district 
in Assam state. The Directorate of National Vector Borne Diseases Control 
Programme has been monitoring the efficacy of antimalarial drugs in 
falciparum malaria parasite in the country since 1978 through 13 
monitoring teams in 11 regional office for Health and Family Welfares with 
the objectives to evaluate the efficacy of first and second line drugs used in 
the treatment of malaria and to provide the information for action to 
formulate revised drug policies. 
The reports on the resistance of Plasmodium falciparum parasites 
to chloroquine and amodiaquine, first observed in 1960-1961 in Colombia 
and in Brazil, were of greater consequence, since together with quinine 
these are the most valuable drugs for the treatment of acute malaria. 
Further reports on drug resistance came from Thailand, Malaysia, 
Cambodia, Phillipines, Indonesia, Vietnam, Laos, Burma and other areas 
of South-East Asia. The occurrence of resistance even in small areas is 
disturbing enough. If this resistance were to become widespread it would 
result in a dramatic depletion of our range of drugs for the prevention and 
treatment of malaria. The countries in different subcontinents showing 
chloroquine resistance are indicated in Maps (II & III). 
In practice, drug resistance is suspected when acute cases of 
malaria {Plasmodium falciparum) do not respond fully to the proper 
treatment with curative drugs, or when parasites are seen in the blood after 
their temporary disappearance after such treatment. Recrudescence of the 
infection may be due to a number of causes. Criteria for recognition of 
suspected resistance of malaria parasites to chloroquine and amodiaquine 
were adopted in 1974, and a standard procedure for determining the 
response of malaria parasites to chloroquine in the field was 
recommended by the WHO. 
An increasing number of malaria epidemics have been documented 
throughout the world. A changing scenario of malaria is observed and it is 
found that malaria had been changing its clinical profile. The classic 
paroxysm is evident in only 40% cases of Plasmodium falciparum and 47% 
cases of Plasmodium vivax. Rest of the cases show continuous or 
remittent type of fever. Association of jaundice along with hepatomegaly 
has also been observed in Plasmodium falciparum and Plasmodium vivax 
infections. Splenomegaly along with respiratory distress, oliguria with 
impaired renal function and convulsion or coma has also been observed 
(Hazra et al. 1998). Available information indicates that Plasmodium 
falciparum has given rise to formidable drug resistant strain in Asia. The 
problem of chloroquine resistance in Plasmodium falciparum is widespread 
and now it is leading towards multiple drug resistance against all major 
antimalarials. 
Sharma (1999) indicated that in higii transmission areas of India 
there are about 30% cases which showed some level of drug resistance 
against standard dosage of curative drugs. Follow up studies showed 
relapses in Plasmodium vivax against standard dosage of therapeutic and 
anti relapse drugs (chloroquine and primaquine) and showing 
complications somewhat similar to that of falciparum malaria. Emerging 
resistance to chloroquine by Plasmodium vivax threatens the health of 
hundreds of millions of people routinely exposed to the risk of infection with 
this organism. Keeping above facts in view, present study was undertaken 
to see the resistance and relapse patterns of Plasmodium falciparum and 
Plasmodium vivax against chloroquine in Aiigarh district of Uttar Pradesh. 
PART C DHFR mutation in P. vivax and P. falciparum 
Plasmodium falciparum is the most lethal of all human malaria 
parasites. This parasite causes epidemics in countries where malaria is 
endemic, resulting in large numbers of death. Drug resistance is becoming 
an increasingly important factor in the effective treatment of malaria. High 
level of resistance to chloroquine has forced some countries to switch their 
first line drug to sulfadoxine-pyrimethamine. However, resistance to this 
drug combination is developing fast, with treatment failures being reported 
in Africa, Asia, Indonesia and South America (Basco et al, 1998; Magesha 
efa/, 2001) 
Antifolate antimalarial drugs interfere with folate metabolism, a 
pathway essential to malaria parasite survival. This class of drug includes 
effective causal prophylactic and therapeutic agents, some of which act 
synergistically when used in combination. Unfortunately, the antifolates 
have proven susceptible to resistance in the malaria parasites. Resistance 
is caused by point mutations in dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS), the two key enzymes in the folate 
biosynthetic pathway which are targeted by antifolates. Resistance to 
these drugs arises relatively rapidly in response to drug pressure and is 
now common worldwide. Nevertheless, antifolate drugs remain first-line 
agents in several countries where chloroquine resistance is wide spread, 
at least partially because they remain the only affordable, effective 
alternative. New antifolate combinations that are more effective against 
resistant parasites are being developed. Combining these antifolates with 
drugs that act on different targets in the parasite should greatly enhance 
their effectiveness as well as deter the development of resistance. 
Resistance of the malaria parasite, especially to the antifolates, will 
continue to make progress in rolling back malaria a formidable challenge in 
the foreseeable future. In Plasmodium falciparum, point mutations in the 
dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) 
genes are the major cause of resistance to antifolate drugs, and such 
mutations have rapidly diminished their clinical effectiveness. Laboratory 
based studies have shown that specific point mutations affecting DHFR 
confer drug resistance, and wide-ranging epidemiological analyses have 
shown that these mutations can account for virtually all of the resistance 
observed in the field. The empiric use of antifolates against malaria long 
predates definitive demonstration of the folate metabolism pathway in 
Plasmodium spp. De novo synthesis of folate pathway in Plasmodium spp. 
was demonstrated over 25 years ago (Ferone, 1977) and although an 
exogenous folate salvage pathway has been found in isolates from around 
the world (Krungkrai et al. 1989), it does not appear to be Plasmodia's 
primary source of folate. The genes encoding the enzymes in the folate 
pathway targeted by existing antifolate drugs, dihydrofoiate reductase 
(DHFR) (Bzik et al. 1987) and dihydropteroate synthetase (DHPS) (Brooks 
et al. 1994; Triglia and Cowman, 1994) have both been cloned and 
sequenced. Mutations observed played a role in resistance to the antifolate 
drugs (Peterson et al. 1988). Pyrimethamine-sulfadoxine combinations 
seemed to be an effective and reasonable alternative to chloroquine but 
resistance to pyrimethamine-sulfadoxine was rapidly gaining ground, 
facilitated by slow elimination from the body. Work related to resistance 
against pyrimethamine-sulfadoxine which is used as second line treatment 
for P. falciparum malaria is in progress in India and abroad. 
A study of pyrimethamine-sulfadoxine effectiveness carried out 
between 1997 and 1999 by Nzila etal. (2000) at Kilifi on the Kenyen coast 
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has shown the emergence of R I and R II resistance to pyrimethamine-
sulfadoxine. More than 65% of isolates had wild type, single or double 
mutant DHFR. High level (45%) of pyrimethamine-sulfadoxine treatment 
failure was recorded in Muheza, Northeast Tanzania by Mutabingwa et al. 
(2001). 
Biswas et al. (2000) assessed the comparative rate of point 
mutation occurring in dihydrofolate reductase (DHFR) and dihydropteroate 
synthetase (DHPS) gene among P. falciparum isolates from India and 
Thailand where use of pyrimethamine-sulfadoxine is at a different rate. 
Ahmad et al. (2004) analyzed mutations in enzymes dihydrofolate 
reductase (DHFR) and dihydropteroate synthetase (DHPS) in 312 field 
isolates of P. falciparum collected from different parts of India. They 
observed higher mutations in gene for DHFR than DHPS, although the 
latter had mutations in more alleles. They also concluded that even though 
pyrimethamine-sulfadoxine is prescribed as a second line of treatment in 
India, the mutations associated with pyrimethamine-sulfadoxine resistance 
continue to be progressively increasing. Kaur et al. (2006) observed 
mutations in dihydrofolate reductase (DHFR) gene of Plasmodium vivax 
against antifolate drugs. They observed wild type dhfr sequence in 70% 
isolates. In 121 isolates they recorded 36 mutations at 11 positions. 
Although findings are available regarding DHFR mutations 
separately for P. vivax and P. falciparum from various countries, there is 
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no report showing DHFR mutations of both species together from the 
same region at a given point, which can assess the cross-specific effect of 
the antifolate treatment. Antifolate drugs pyrimethamine and sulfadoxine 
are commonly used to treat P. falciparum malaria. However, they can also 
affect the P. vivax parasite, if it co-exists with P. falciparum as both species 
have common drug targets. Keeping this fact in consideration present 
study was planned to see the mutations in dihydrofolate reductase (DHFR) 
enzyme of P. falciparum against antifolate drugs pyrimethamine and 
sulfadoxine. A comparison is also made in overall DHFR mutation rate in 
P. vivax and P. falciparum in Aligarh. 
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Historical Review 
HISTORICAL REVIEW 
Malaria has been known from antiquity, the earliest information 
came from ancient Egypt and various Papyri. The first accurate clinical 
description of malaria was given by Hippocrates in 400 BC (Boyd 1949), 
who mentioned the classic triad of chills, fever and sweating and analyzed 
the characteristic periodicity of various phases of malaria. The specific 
fever caused by malaria parasite known as "Agues" received the Italian 
name "Malaria" since it was then widely believed that their cause was 
related to the foul air common near marshy areas. The most important 
event in the history of malaria took place towards the end of 19"^  century 
when the workers in the field of bacteriology and pathology were 
discovering the cause of infectious disease, observing the morbid change 
in the organ and the tissues perceived the role of insects in the 
transmission of some infections. 
In 1880 Laveran, French army surgeon first saw and described 
malaria parasite in red blood cells. More than 100 Plasmodium species 
have been described causing malaria in a wide range of vertebrates and 
only four species infect men which are P. vivax, P. falciparum, P. ovale 
and P. malariae. The generic name Plasmodium was given by Marchiafava 
and Celli in 1885. Differential description for P. vivax and P. malariae were 
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given by Grassi and Feletti as early as in 1892, for P. falciparum by Welch 
in 1897 and for P. ovale by Stephens in 1922. 
Romanowsky (1890) in Russia developed a new method of staining 
the malaria parasites in blood films and this together with the improvement 
of microscope made further studies of Plasmodium much easier. However 
the way in which the disease was transmitted from man to man was still a 
mystery, although few early and inspired guesses pointed to the possible 
association between swamps, mosquitoes and fever. In 1884 Patrick 
Manson put forward a theory that malaria is transmitted from man to man 
by mosquitoes. The final elucidation of actual mode of transmission was 
not forthcoming until 1897 when Ronald Ross in Hyderabad found that 
mosquitoes with spotted wings (i.e. Anopheles) when fed on the patient 
whose blood contained numerous crescent, 4 days later developed into 
peculiar pigment cells in the gut wall of mosquitoes. This experiment 
constituted the first demonstration of the eariy stages in the development 
of P. falciparum in the mosquito. In 1898 Grassi, Bignami and Bastianelli 
described the life cycle of human malaria parasite in Anopheles mosquito. 
James in 1931 reviewed the Grassi's theory and suggested that 
sporozoites soon after entering the body invade reticulo-endothelial cells. 
Fairiey's (1945) observation on P. vivax showed that sporozoites vanished 
from circulatory blood within 30 minutes after inoculation. Later on it 
became evident that sporozoites first enter liver and complete pre 
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erythrocytic schizogony within a few days and then enter blood circulation 
again to initiate erythrocytic schizogony in RBC followed by gametogony. 
The first anopheline survey was done by Challam (1923) from 
Kamrup district of Assam. Later, the surveys were carried out by 
Christophers (1925), Stickland (1929), Ramsay (1930), Macdonald and 
Choudhury (1931), Gupta and Mazumdar (1932), Rice and Savage (1932) 
in Assam. In other state, surveys were candied out by Shortt (1924) in 
Meghalaya, Afridi et al. (1938) and Jaswant and Jacob (1943) in Gujrat, 
Mortimer (1946) in Manipur, Mishra and Dhar (1955) in Tripura, Mishra 
(1956) and Sen et al. (1973) in Arunachal Pradesh, Rajagopal (1976) in 
Meghalaya, Bhatia et al. (1958b) and Kaira and Wattal (1965) in Uttar 
Pradesh. In recent years anopheline surveys were carried out by Malhotra 
et al. in Nagaland, Manipur and Mizoram in 1982, 1983 and 1984, 
respectively. Singh et al. (1985) and Yadav et al. (1989) surveyed 
anopheline mosquitoes in Gujrat. Anopheline species of Uttar Pradesh 
were recorded by Nagpal etal (1983) and Tiwari etal. (1997). 
Till date there are 420 species of Anopheles throughout the world. 
Out of these 70 are well-known malaria vectors. In India 58 species of 
Anopheles are recorded, out of which six are considered as primary vector 
and four are secondary vectors (Rao,1984). Among the primary vectors 
An. culicifacies is most important and is responsible for transmission of 60-
70 % cases of malaria in India as reported by Sharma (1984). An. 
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culicifacies has a wide distribution in Indian subcontinent, West Asia and 
Middle East. It is widely distributed throughout India except in Andaman & 
Nicobar Islands. 
Anopheles culicifacies feed on warm-blooded animals with some 
preference for human or certain animal hosts. A fair population of An. 
culicifacies was found exophagic and exophilic in nature as eariier reported 
by Kaira (1978) and Nagpal and Sharma (1985). Anopheles culicifacies 
breeds in the variety of habitats such as irrigation channels, river bed 
pools, paddy fields, seepage water from canals and dams, rain water 
collection and borrow pits. It also breeds in hoof marks and wheel ruts. 
Being monsoon associated species maximum breeding occurs after the 
rains. Adults visit houses, cattle shades and mixed dwellings and bites 
throughout the night with higher frequency between 1900 to 0400 hrs. 
Variations are there from place to place and season to season. The flight 
range is short but at high densities and under favourable climatic 
conditions it extends upto 3 km (Nagpal and KaIra, 1997). 
An. culicifacies although basically a zoophilic species, builds up very 
high-density levels and at that time some population diverts to man. Till 
1993 more than three lac specimens from different parts of the country 
have been collected and dissected to investigate the role of this species in 
malaria transmission. Out of these about 700 specimens were found 
positive for sporozoites and more than 400 specimens for oocysts (Nagpal 
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and Kaira 1997). This species is mainly responsible for fulminating 
epidemics in North Westem part of Punjab, Rajasthan and Uttar Pradesh 
and species transmits malaria during the rainy season (i.e. July to October) 
in most parts of the country. 
As far as vector incrimination is concemed An. culicifacies was 
incriminated as malaria vector for the first time in India at Ennore (Tamil 
Nadu) in 1902 by Stephens and Christophers. They found six An. 
- culicifacies infected with sporozoite and again in the same year they 
incriminated An. culicifacies from Punjab. In Uttar Pradesh it was Graham 
who reported An. culicifacies as malaria vector from Kosi in 1910. In 1913 
Graham reported An. culicifacies as a vector of malaria from Meerut. 
Mayne (1928) and Bhatia et al. (1958) incriminated An. culicifacies from 
Saharanpur, Bulandshahar district, respectively. An. culicifacies was 
incriminated from Gadarpur, Ghaziabad, Delhi and Bareilly (Choudhury et 
al. 1983, Annual report MRC 1983 and Ansari e^ al. 1984). Ansari et al. 
(1986) and Prasad and Sharma (1990) incriminated An. culicifacies by 
finding sporozoite in salivary gland from a few villages of Meerut District 
and Banda PHC of Shahjahanpur. An. culicifacies was also incriminated 
from other parts of India. Nagpal and Sharma (1986) incriminated An. 
culicifacies from Cuttak, Phulbani and Sambalpur in Orissa state. 
GunaseKaran et al. (1989) and Kulkarni (1990) reported An. culicifacies 
from Koraput (Orissa) and Baster (Madhya Pradesh). 
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Routine urban malaria vector An. Stephens! breeds in domestic 
containers such as overhead tanks, underground tanks, ground level 
tanks, cistem wells, coolers and many other domestic water storage 
containers. Breeding of An. Stephens! in irrigation channels were recorded 
in Delhi by Covell (1939) and in rice fields in district Mandia in Madhya 
Pradesh by Singh et al. (1989).This species is responsible for the 
transmission of malaria in urban areas of the country and rural areas of 
Rajasthan. In India this species is recorded from all the states. An. 
Stephens! is an efficient malaria vector and till 1987 about 27 thousands 
mosquitoes were dissected from different town/cities of the country, out of 
these 150 were found positive for sporozoite and 251 for oocysts (Nagpal 
andKaIra, 1997). 
An. fluviatilis is an efficient vector of malaria in India and transmits 
the disease along with An. culicifacies in U.P. Terai and Orissa and with 
An. minimus in North Eastem states. This species prefers to breed in slow 
moving water such as field channels, slow moving streams, seepage 
channels of dams and irrigation channels. This species also breeds in 
wells, borrow pits and rice fields in foothill areas. An. fluv!at!l!s was 
zoophilic in nature during 1930's in U.P., Terai (Clyde, 1931). In 1952 
Srivastava and Chakraborty established the role of this species in malaria 
transmission by getting 11.6% sporozoite positivity rate in Kichha district, 
Nainital. In India till date more than seventy thousand An. fluviatilis have 
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been dissected from different part of the country for gut and gland 
infections. Out of these 1300 specimens were found positive for 
sporozoites in salivary gland and 1700 with oocysts in gut (Nagpal and 
Kaira, 1997). At present An. fluviatilis is found predominantly zoophilic and 
have very limited role in malaria transmission in U.P., Terai area (Nanda et 
al. 1996). 
An. minimus is a small size mosquito hence Theobald named it as 
minimus. Its preferable breeding sites are streams, rivers, in i^gation 
channels and tea gardens, which have a perceptible flow of water. This 
species is highly anthropophilic and is a primary vector of malaria all over 
its range of distribution in oriental region. In India this species is a primary 
vector in North East region especially in tea garden which is located in foot 
hills (Ramsay, 1930, Gupta et al. 1933, Iyengar, 1939) and in Jeypore hills 
(Senior white, 1938.; Viswanathan et al. 1941). However subsequent 
studies after application of DDT showed the absence of this species from 
Terai region of Uttar Pradesh (Chakraborty and Singh, 1957) and Burnihat 
areas of Meghalaya (Rajagopal, 1976). But Bhatnagar et al. (1982) 
reincriminated it from Nagaland, Das and Baruah (1985) from Mizoram, 
Dutta and Baruah (1987) from Arunachal Pradesh and Wajihullah et al. 
(1992) from Assam. More than 1.5 Lac specimens of this species have 
been dissected and out of these 1350 specimens were found with 
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sporozoites and/or oocysts in their gland and gut (Nagpal and Kaira, 
1997). 
An. sundaicus is coastal species and breeds in brackish water and 
some times in fresh water. In India its previous distribution on the main 
land extended upto coastal areas of Andhra Pradesh, Orissa, Tamil Nadu 
and West Bengal (Covell and Singh, 1943; Senior White, 1937) but is now 
restricted to Andaman and Nicobar Islands only (Nagpal and Sharma, 
1983, Roopkumari and Sharma, 1994). An. sundaicus is an efficient vector 
of malaria in Andaman & Nicobar Island. 
An. dims is a wild mosquito and transmits malaria in deep-forested 
areas. This species breeds in jungle pools, pools situated on the side of 
rocky streams, rain water collections, borrow pits and stagnant waters in 
jungles (Rao, 1984). This species is highly anthropophilic and bites human 
in forest areas out door and indoor both. In India this species transmits 
malaria in North Eastern region only, although the species is recorded from 
Tamil Nadu, Andaman Islands, Kamataka and Kerala (Dutta et al. 1989; 
Nagpal and Sharma 1995 and Das et al. 1990). More then 4000 
specimens of this species were dissected for gut and gland positivity and 
out of these 44 were found positive for sporozoites and 36 for oocysts in 
gut (Nagpal and Kaira, 1997). Das and Bamah (1985), Dutta et al. (1989) 
and Das et al. (1990) incriminated An. dims from forest areas of Mizoram, 
Assam and Arunachal Pradesh. 
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Resistance to antimalarial drugs is proving to be a challenging 
problem in malaria control in most parts of the world. Drug resistance is the 
ability of the parasite species to survive and/or multiply despite the 
administration and absorption of a drug given in doses equal to or'higher 
than those usually recommended but within the limit of tolerance. 
Discovery of chloroquine revolutionalised the treatment of malaria, pushing 
quinine to sidelines. Plasmodium falciparum developed resistance to 
chloroquine in the 1950s (Wellem & Plowe, 2001). Resistance began from 
two epicenters, Columbia (South America) and Thailand (South East Asia) 
in the early parts of 1960s, since then resistance has been spreading 
worldwide and is now reported in 80% of 92 countries where malaria 
continues to be major killer, while resistance to newer second and third line 
degree continue to grow. 
Epidemiological studies conducted in Gambella, Southern Ethiopia, 
Thailand and India (Nigatu et al. 1992, Thimasank et al. 1995 and Sharma 
1996) indicate that the most probable contributing factors for malaria 
transmission pattern were the rehabilitation and resettlement programmes 
and agricultural activities undertaken in these countries during past ten 
years that may have brought changes in socio-economic situation and 
environmental factors. Most of the work in the field of malaria is being done 
on Plasmodium falciparum causing malignant infection and Plasmodium 
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wVax which cause benign infection. Lot of mortality takes place because of 
Plasmodium falciparum infection each year and therefore, much attention 
is paid to this parasite. It is found that Plasmodium falciparum infection is 
emerging in endemic areas (Mandal et al. 1998). A competition is going on 
between Plasmodium vivax and Plasmodium falciparum to gain upper 
hand as a result of which a changed scenario of malaria transmission is 
observed. 
Most of the reports and cross checking in different part of the world 
indicate that Plasmodium falciparum has developed resistance against 
standard dosage of curative drugs. As for drug resistance is concerned 
Plasmodium falciparum showed resistance against chloroquine, 
amodiaquine, metakeifin, fansidar and mefloquine. Resistance in 
Plasmodium falciparum to amodiaquine and quinine was reported in 
Madang province of Papua New Guinea by Al Yaman et al. (1996). 
Multiple drug resistance was observed in falciparum malaria by McGready 
et al. during 1991-1996 in pregnant women living in westem border of 
Thailand. They were treated with either mefloquine, quinine or both. Out of 
those treated with mefloquine 6% failed to clear parasitaemia by day 7 and 
28 % by day 24. 
Therapeutic effects of chloroquine in combination with quinine in 
uncomplicated falciparum malaria were studied in 50 Thai men by 
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Vanojanontas et al. (1996). They treated all the patients for 7 days with 
quinine (10 mg base / kg, every 8 hourly). A group of patients selected 
randomly was given oral tetracycline (4 mg / kg, 4 times daily) for the same 
period while patients in other group were given chloroquine for the first 
three days. Overall clearance time in the chloroquine or tetracycline group 
were not significantly different. Recrudescences (R-l level) were higher in 
chloroquine group than in tetracycline. Survey conducted during last 
decade showed that Plasmodium falciparum has become resistant to 
chloroquine in Pakistan and Afghan refugees (Shah et al. 1997). A 
repeated in vivo survey indicated that prescription of chloroquine can lead 
to 15 % increase in the frequency of resistance in a single year. The 
therapeutic efficacy of chloroquine was assessed by Mharakurwas et al. 
(1997) who reported resistance in 52% patients following chloroquine 
treatment. In 64 cases of uncomplicated falciparum malaria in Zimbabwe 
they noticed a modest reduction in a sexual parasite density and clinical 
symptom. However, there was an appreciable therapeutic failure of 
chloroquine which has declining clinical value as the first line of 
presumptive treatment of uncomplicated malaria. It is therefore 
recommended in Zimbabwe that the second line antimalarial sulphadoxine-
pyrimethamine should be distributed to health centre level for patients 
suffering from malaria. Bojang et al. (1998) noticed failure of fansidar and 
chloroquine in Gambian children. In India Ghosh et al. (1992) reported that 
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58.3% Plasmodium falciparum cases did not respond to single dose of 
chloroquine (10 mg base/ kg) in vivo test. With standard dose of (25 mg 
base / kg) 31.2 % cases showed resistance i.e. Rl (5.6%), Rll (9.4%) and 
Rill (6.2%) levels. Garg et al. (1996) treated 17 uncomplicated falciparum 
malaria patients resistant to chloroquine with 3 tablets of sulphadoxine-
pyrlmethamine. Out of 17, 14 patients responded and were sensitive while 
3 patients showed Rll grade resistance to sulphadoxine- pyrimethamine. 
These 3 patients then responded to a 7 day course of quinine + 
doxycycline. Hazra et al. (1998) studied 60 cases of Plasmodium 
falciparum and 165 cases of Plasmodium vivax clinically. It was observed 
that malaria had been changing its clinical profile. The classic paroxysm 
was evident only in 40% cases of Plasmodium falciparum and 47.27% of 
Plasmodium vivax malaria. On the other hand remittent type of fever had 
been observed in 40% and 27.2% cases of Plasmodium falciparum and 
Plasmodium vivax, respectively. Absence of classic paroxysm of fever, in 
association with splenomegaly was reported in 80 % and 63.6% of this 
infection in conjunction with nausea and vomiting leading to clinical 
mimicry with infective hepatitis. Splenomegaly which has been described 
as cardial feature of malaria was observed in 40% cases with Plasnhodium 
falciparum and 18.18% Plasmodium vivax. Coexistence of intense fever 
was observed in 3.35% of falciparum and 2.6% of vivax malaria. 
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Emerging resistance to chloroquine by P. vivax threatens tiie heaitli 
of tiie hundreds of millions of people routinely exposed to the risk of this 
organism. Chloroquine has been the first line therapy for vivax malaria 
since 1946 (Coatney, 1963 and WHO, 2001). Resistance to P. vivax was 
unknown until 1989, when Australians repatriated from Papua New Guinea 
failed routine treatment (Rieckmann et a/. 1989). Subsequent reports 
affirmed that finding, and chloroquine resistant P. vivax was reported from 
Indonesia, Myanmar and India (Baird et a!., 1991; Collignon, 1991; 
Schuurkamp et a/. 1992, Marlar-Than et a/. 1995; Myat-Phone-Kyaw et al. 
1993, Garg etal. 1995; Van Den Abbeele ef a/.1995). 
Plasmodium vivax infection caused by strains with low sensitivity to 
primaquine are widespread in Westem Pacific and south-east Asia and 
have recently been reported from Central America as well (Singnorini et al. 
1996). A case of primaquine failure in Plasmodium vivax infection was 
recorded in Guatemala. A 28 year old Italian woman had vivax attack 2 
months after returning from Guatemala who was treated there with 
chloroquine course (1500 mg over 3 days) along with primaquine (15 mg/ 
day) for 14 days. Two months later she had a relapse that was again 
treated with chloroquine and primaquine at the same dosage. After 3 
months a second relapse occurred. This time primaquine (30 mg/day for 
14 days) was administered. The patient remained well during a follow up 
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period of 6 months. Dosage of primaquine as higii as 6 mg/kg body weight 
is recommended in the treatment of vivax malaria in Central America. 
Vivax malaria is most frequent imported malaria in Japan comprising 
about 60% of the total cases. Patients were usually treated after acute 
phase therapy of chloroquine with standard course of primaquine (15 mg/ 
day for 14 days) as curative therapy. Recently however cases of relapse of 
vivax malaria after this standard primaquine therapy are reported from 
various countries such as Japan, New Guinea, Thailand and Indonesia. In 
contrast the relapse rates of cases acquired in India are low. Most of the 
relapsed cases are successfully treated with either of these regimen (i) 20 
mg/ day for 7 days (ii) two courses of the standard primaquine therapy 
given one month apart (iii) 15 mg/day for 21 days without noticeable side 
effects. It is imperative to establish the most appropriate regimen with 
primaquine for curative treatment of vivax malaria contracted in the areas 
mentioned above. Smoak etal. (1997) studied relapse patterns in US army 
troops in Somalia. Following initial attack of malaria, 60 of 75 cases 
received a standard course of primaquine (15 mg base daily for 14 days). 
26 of 60 soldiers subsequently relapsed with a failure rate of 43%. 
Soldiers had second relapse following primaquine therapy after both 
primary attack and first relapse. 3 of these soldiers had received a higher 
dose of primaquine (30 mg base daily for 14 days) after their second 
attack. The apparent ineffectiveness of primaquine therapy in preventing 
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relapse suggests the presence of primaquine resistant Plasmodium vivax 
strain in Somalia. 
Studies conducted on Plasmodium vivax infections indicate that the 
parasite show tolerance against both therapeutic and anti relapse drugs. A 
study on relapse/reinfection pattern of Plasmodium vivax was conducted in 
District Shahjahanpur by Prasad et al. (1991) who reported maximum 
number of relapse / reinfection in a 47 year old male patient, who suffered 
8 times relapses. They have indicated that relapse rate was high in males 
(70.2%) as compared to females (29.8%). A study on relapse pattern of 
Plasmodium vivax was conducted by Sharma et al. (1990) In Kheda district 
of Gujrat where relapsing tendency in Plasmodium vivax was observed 
within 8 months of primary attack. Relapse rate was 2.6% within one year 
in patients treated with 5 days course of primaquine. Immune response of 
Plasmodium vivax in a cross-section of the population in Delhi area was 
studied by Ray et al. (1994). They observed antibodies against crude 
blood stage antigen in majority of the individuals who were acutely infected 
with Plasmodium vivax. A study on Plasmodium vivax relapse patterns 
was also conducted in Kheda hospital by Srivastava ef al. (1996). They 
treated one group of patients with 600 mg chloroquine and other with 600 
mg chloroquine and 50 mg pyrimethamine which yielded 28.3 % and 
27.3 % relapse rates, respectively. They have also noticed more short-
term relapse (within 2-3 months) and a few long-term relapse. A five year 
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epidemiological study of patients attending malaria clinic in Delhi was 
conducted by Adak et al. (1998) to find out the relapse rate in Plasmodium 
vivax infections. They have also observed seasonal congelation between 
the primary infection and subsequent relapses, the duration of the 
incubation period, and the pattern of relapse. They recorded relapse rate in 
the range of 23% to 44% depending on the short and long durations of the 
follow up. 
It has also been reported recently that Plasmodium vivax has 
developed resistance to chloroquine. Baird ef al. (1997) noticed 
chloroquine resistant strain of Plasmodium vivax in Indonesia, 21 patients 
infected with Plasmodium vivax were given chloroquine. 3 of them had 
recun-ent asexual Plasmodium vivax parasitaemia between day 14 to 18 
despite of the effective levels of chloroquine at the time of recurrence. 
Resistance to standard chloroquine therapy by Plasmodium vivax was 
noticed in 14% cases. Marlerthan et al. (1995) noticed resistance to 
standard chloroquine therapy by Plasmodium vivax infections, in Myanmar. 
50 patients with Plasmodium vivax infection were treated with standard 
regimen of chloroquine phosphate (1500 mg over 3 days) followed by 45 
mg primaquine immediately and then weekly for 8 weeks. Patients showed 
recrudescence between day 3 and 14 with Rl, Rll and RIM pattern in 1, 3 
and 3 patients, respectively. All the chloroquine resistant cases were again 
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treated with 1500 mg chloroquine and no further recrudescence or relapse 
were detected. 
The development of resistance to sulfadoxine-pyrimethamine by 
Plasmodium parasites is a major problem for the effective treatment of 
malaria, especially P. falciparum. Although the molecular basis for parasite 
resistance is known, the factors providing the development and 
transmission of these resistant parasites are less clear. A number of 
research laboratories including our own have reported results mutations 
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associated with sulfadoxine-pyrimethamine resistance in Plasmodium 
falciparum and Plasmodium vivax. 
Chloroquine was antimalarial treatment of choice by and large during 
the second half of 20"" century. Now it is replaced by sulfadoxine-
pyrimethamine combination in most endemic countries throughout the 
world. In Tanzania increasing rate of chloroquine resistance led to change 
its first line treatment of uncomplicated malaria to sulfadoxine-
pyrimethamine. This antifolate combination seemed to be an effective and 
reasonable alternative but resistance to sulfadoxine-pyrimethamine was 
rapidly gaining ground, facilitated by the slow elimination from the body. 
High level (45%) of sulfadoxine-pyrimethamine treatment failures were 
recorded in Muheza, North East Tanzania by Mutabingwa et al. 2001; 
Nazila et al. 2000, observed that when a combination of pyrimethamine 
and sulfadoxine was used in Kenya, drug resistant parasites selected 
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rapidly. A study of pyrimethamine- suifadoxine effectiveness was carried 
out between 1997 and 1999 at Kilify on the Kenyan Coast had shown the 
emergence of R I and R II resistance to pyrimethamine- suifadoxine 
(residual parasitemia 7 days after treatment) in 39 out of 240 (16.25%) 
patients. They concluded that prevalence of triple mutant DHFR- double 
mutant DHPS combination may be an operationally useful marker of 
predicting the effectiveness of pyrimethamine- suifadoxine as a new 
malaria treatment. Sasithan et al. 2000 observed therapeutic response of 
most widely used antimalarial in 207 adult patients with Plasmodium vivax 
malaria in Bangkok hospital for tropical disease and found artesunate and 
artemether as most effective and pyrimethamine- suifadoxine as least 
effective. Gatton et al. 2004 worked on evolution of resistance to 
pyrimethamine-sulfadoxine in P. falciparum. His findings indicate three 
stages in the development of drug resistance. The first is the collection of 
existing parasites with genetic mutations in the DHFR and DHPS gene and 
it was driven by long half life of pyrimethamine- suifadoxine combinations. 
The second stage involves the selection of parasites with allelic types of 
higher resistance within the host during an infection. And the third stage, 
clinical treatment failure becomes prevalent as the parasites develop 
sufficient resistance mutation to survive therapeutic doses of the dmg 
combinations. They emphasized on importance of correct treatment of 
confirmed malaria cases to avoid development of parasite resistance to 
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pyrimethamine- sulfadoxine. Ingrid et al. (2004) concluded in their study 
that quinine 3-days combine to pyrimethamine-sulfadoxine is still relatively 
effective in Chittagong Hill Track of Bangladesh. However, they suggested 
if this regimen is continued to be widely used, further development of 
pyrimethamine-sulfadoxine resistance and reduced sensitivity to quinine 
are to be expected. The genotyping results suggest that neither 
chloroquine nor pyrimethamine- sulfadoxine can be considered a reliable 
treatment for P. falciparum malaria any longer in Bangladesh. 
In India, work related to resistance against pyrimethamine-
sulfadoxine is in progress. Biswas et al. 2000 assessed the comparative 
rate of point mutation occurring in dihydrofolate reductase (DHFR) and 
dihydropteroate synthetase (DHPS) gene among P. falciparum isolates 
from India and Thailand where the use of pyrimethamine-sulfadoxine, is at 
a different rate. They observed that among Indian isolates, DHFR point 
mutation were very frequent while they had very few DHPS mutation. The 
pattern of mutation in Thai samples was different as most were associated 
with point mutation in DHFR and DHPS gene. Valecha et al. 2006 
indicated that Indian isolates of P. vivax exhibit only double mutations 
DHFR in vitro. In our studies (Alam et al. 2007) on assessment of cross-
species impact of antifolate drug treatment we observed that the overall 
DHFR mutation rate for P. vivax was lower than that of P. falciparum. 
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However, both species of Plasmodium followed similar trends of DHFR 
mutations. 
Antifolate antimalarial drugs interfere with folate metabolism, a 
pathway essential to malaria parasite survival. Unfortunately the antifolates 
have proven susceptible to resistance in malaria parasite. Resistance is 
caused by point mutation in dihydrofolate reductase (DHFR). The first 
mutation occurs at S108N codon followed by C59R, N51I and I164L 
mutations (Gregson and Plowe, 2005). One could observe single, double, 
triple, or quadruple PFDHFR mutations depending on the level of drug 
resistance. Plasmodium falciparum isolates with increased numbers of 
PFDHFR mutations were found to show a higher degree of pyrimethamine 
resistance (Gregson and Plowe, 2005). Indeed, the falciparum malaria 
patients containing quadruple PFDHFR mutations showed a treatment 
failure against this drug (Wang et al. 1997b, Gregson and Plowe, 2005). 
This antifolate drug also affects the Plasmodium vivax parasite since both 
contain the same target enzyme (de Pecoulas et al. 1,998a). 
Pyrimethamine resistance in P. vivax is associated with two key DHFR 
mutations, S58R and S117N, which are equivalent to the C59R and 
S108N mutations of PFDHFR (de Pecoulas et al. 2004). In addition, other 
mutations (113L, P33L, F57L/I, T61M, S117T, 1172V, and I173L) in 
PVDHFR have also been reported (Imwong et al. 2001, 2003; Brega et al. 
2004; de Pecoulas et al. 1998a, 1998b, 2004; Hasting et al. 2004, 2005; 
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Na et al. 2005; Kaur et al. 2006; Schunk et al. 2006 and Valecha et al. 
2006). Similar PVDHFR mutations at these codons except for I13L, P33L, 
1172V, and I173L have also been reported in India by various workers 
(Imwong et al. 2001; Kaur et al. 2006 and Valecha et al. 2006). 
The in vitro and in vivo data on PVDHFR mutations have now clearly 
established the association between pyrimethamine resistance and point 
mutations (Imwong et al. 2001; Leartsakulpanich et al. 2002; Tahar et al. 
2001, Tjitra et al. 2002, and Hasting et al. 2004, 2005). For example, the 
wild type PVDHFR enzyme expressed in Escherichia co//showed a higher 
catalytic activity than the mutant type of enzyme (Tahar et al. 2001 and 
Leartsakulpanich et al. 2002). Similarly, wild-type and different mutant 
alleles of PVDHFR were expressed in Saccharomyces cen/isiae and 
tested for their susceptibilities to pyrimethamine. The yeast cells harboring 
the mutant PVDHFR construct showed their survival at a higher 
concentration of pyrimethamine than those cells that were harboring the 
wild type PVDHFR construct (Hasting e^ al. 2004). The degree of 
pyrimethamine resistance in P. vivax also increases with the sequential 
addition of each mutation in DHFR gene, and extremely resistant parasites 
carry an S117T mutation (Hasting et al., 2004, 2005). Therefore, the 
PVDHFR allele with quadruple mutations (F57L plus S58R plus T61M plus 
S117T) exhibited the highest level of pyrimethamine resistance in 
Saccharomyces cen/isiae system (Hasting et al. 2005). The P. vivax 
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malaria patients harboring this quadruple mutation were also unable to 
clear the parasite with pyrimethamine (Tjitra et al. 2002). The DHFR 
mutations of both Plasmodium species have now been used as markers to 
assess antifolate drug pressure in the field (Wang et al. 1997b; Imwong et 
al. 2001; Tjitra et al. 2002; Ahmad et al. 2004; 2006a, 2006; de Pecoulas 
et al. 2004; Hasting et al. 2004; Gregson & Plowe, 2005; Na et al. 2005; 
Kaur et al. 2006; Schunk et al. 2006, Valecha et al. 2006). 
A molecular epidemiological survey of samples from four countries, 
each with increasing levels of sulfadoxine-pyrimethamine resistance, Mali, 
Kenya, Malawi and Bolivia demonstrated that the number of both DHFR 
and DHPS mutations rose in parallel with the prevalence sulfadoxine-
pyrimethamine clinical resistance in the populations (Plowe et al. 1997). 
The findings supported the hypothesis that increasing numbers of DHFR 
and DHPS mutations lead to in vitro sulfadoxine-pyrimethamine failure. 
The DHFR C50R mutation was found in 52.5% of the Bolivian samples 
and appeared to take the place of the African C59R mutation, which in 
contrast, was present in 61% of Kenyan field isolates (Nzila-Mounda et al. 
1998). The Bolivia repeat was found in 44% of the samples from Bolivia, 
and both the Bolivia repeats and C50R mutations were found only in the 
presence of DHFR N51I mutation. Furthermore, the Bolivia repeat 
occurred only with the DHFR I164L mutation, suggesting a compensatory , 
role for the repeat. Interestingly most of the DHFR C50R occured with the 
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wild- type isoleucine I164L. Genetic transformations studies in yeast 
suggest that C50R has an effect similar to C59R in combination with I164L 
(Cortese and Plowe, 1998). In another molecular survey of DHFR and 
DHPS mutations from around the world (Wang et a/.1997a), increased 
number of mutations in both DHFR and DHPS were seen in areas with 
higher levels of sulfadoxine-pyrimethamine resistance. The Middle East 
had the lowest level of in vivo resistance and only mutations in DHFR were 
seen, with S108N being the most frequent. The 18 samples from Mali were 
all wild type with respect to DHFR, except two samples which were triply 
mutant at S108N/C59R/N51I. Kenya and Tanzania both had the 
S108N/C59R/N51I DHFR triple mutant. DHFR mutation I164L was found 
only in Vietnam. 
Recent studies have demonstrated a common ancestry for highly 
antifolate resistant P. falciparum. It had been previously shown that the 
chloroquine resistance confen i^ng mutations in P. falciparum pfcrt arose at 
a limited number of foci outside of Africa and that African chloroquine 
resistant malaria originated from a South East Asian ancestor (Wellems & 
Plowe, 2001). 
The worldwide distribution of DHFR and DHPS mutation is not 
uniform, although many universal mutations do exist. To date, the DHFR 
11641 mutation is absent from Africa and only seen in areas of Latin 
America with high rates of sulfadoxine-pyrimethamine clinical failure. The 
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DHFR I164L mutation is found with some regularity in Southeast Asia 
where rates of suifadoxine-pyrimethamine clinical failure are highest. 
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Part A 
Vector Screening and 
Incrimination 
PART A Vector Screening and Incrimination 
MATERIALS AND METHODS 
For vector screening mosquitoes were collected from Aligarh from 
December 2000 to November 2002. Mosquito collection was made from 
seven different localities of Aligarh. These localities were Fort, Bhamola, 
Jamalpur, Dhon-a, Ramghat Road, Delhi Gate and Sasni Gate, Adult 
mosquitoes were collected with the help of suction tube in the early 
morning and evening from different resting places viz. cattle sheds human 
dwellings and mixed dwellings throughout the year thrice in a week. For 
vector screening mosquitoes were anaesthetized with ether and 
identifications were made on the basis of their morphological features, 
namely presence or absence of bands and speckling on the legs, presence 
or absence and number of bands and patches on costa and subcosta of 
wings, scaly interruptions on wing veins, banding patterns of palpi with the 
help of standard regional pictorial keys of Wattal and Kaira (1961). 
For vector incrimination three suspected anthropophilic species viz. 
An. culicifacies, An. Stephens! and An. annularis were collected from 
human dwellings of different localities during high transmission season (i.e. 
August to October). The mosquitoes were anaesthetized with ether and 
identified with the help of standard regional pictorial keys of Wattal and 
KaIra (1961). Identified mosquitoes were dissected to look for salivary 
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gland infection. Sporozoite positive slides were stained with Leishmann's 
stain as described by Choudhrey and Ghosh (1982) and sporozoite 
positivity rate was worked out. For human blood index, blood smears were 
prepared from the gut of fully fed female Anopheles on Whatman filter 
paper No. 1 and analyzed by counter current electrophoresis. 
Analysis of mosquito blood meal: 
1- Sample preparation (Antigen): 
For antigens blood meal samples were punched with the help of a 
paper punch and soak in the tube containing 50 |jl of normal saline 
(0.85%) for 2 to 3 hours at room temperature. 
2- Antisera: 
Human and bovine antisera titred at 1:20,000 were obtained from 
serologist to the Government of India, 3 Kyd Street, Kolkatta. One part of 
the antisera was mixed with two parts of normal saline (0.85%) for routine 
use. 
3- Buffers: 
Barbltone Buffer 0.1 M 
0.5 M Barbltone Buffer - 200 ml 
(Stock solution of gel diffusion) 
Distilled water 800 ml 
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Working gel buffer 
Stock solution - 100 ml 
Calcium Lactate - 0.125 gm 
Distilled water up to - 250 ml 
Working tank buffer 
Stock solution 900 ml 
Calcium Lactate 0.34 gm 
4- Precoating of the slides: 
Precoating gel: 
Agarose - 0.2 gm 
Working gel buffer - 50 ml 
Distilled water - 50 ml 
The solution was boiled in a water bath till it became water clear 
(transparent). Slides were cleaned with spirit and then dipped in the 
Precoating solution. Slides were dried at upright position. Precoating the 
slides ensures that a firm grip will be maintained on the gel overlay so that 
it is not detached by the suction punching device used to cut the wells. 
Precoating helps in the adherence of the gel layer to the slide during 
washing and staining process also. 
5- Gel layering: 
Agarose 1.5 gm 
Working gel buffer 100 ml 
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The agarose was dissolved by boiling in a water bath to obtain a 
clear solution. The gel solution was cooled to 55 to 60°C. 3.5 nnl of the 
solution was poured on a precoated glass slide with the help of a 5 ml 
pipette and left for 5-10 minutes at room temperature for gelling. The slide 
with the gel layer was then kept inside a moist humid box at 4°C 
(refrigerator) for 1 hour. Extra gel solutions were stored in the refrigerator 
after adding 1% merthiolate. For reuse it was heated as before in a water 
bath. 
6- Cutting the wells: 
A template of the pattern of the wells was drawn on paper to 
facilitate the working. The template was placed below the gel slide and the 
wells of 1.5 mm diameters were punched on the gel layer with the help of a 
steel punch of the same diameter. Agarose piece was removed frbm the 
well with the help of needle. A dropper of thin glass with a outside diameter 
of 1.5 mm can also be used. 
7- Arrangementof the wells: 
Wells were made on a standard microscopic slide of 75 mm x 25 
mm dimension. Blood meal smears were tested against human and bovine 
antisera. Negative control was also run side by side. The distance between 
the two wells of row and a set was 5 mm while distance between the two 
sets was 1 cm. 
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8- Loading of wells: 
For loading the wells of each set two finely drawn pasture pipettes 
were used. One for antisera and other for antigen.The negative side wells 
were loaded with antigen (eluted blood meal extract) and the positive side 
wells were loaded with antisera (human and bovine). Pipettes were 
washed thoroughly with distilled water after loading of each sample. On the 
left side of the slide indicator dye was placed. 
9- Electrophoresis: 
Slides were mounted on the electrophoretic chamber filled with tank 
buffer and were connect with the help of filter paper wicks (3 mm filter 
paper) and finally lid was closed. Electrophoresis was canried out at 150 
volts (constant voltage) for 15-20 minutes at room temperature. After the 
electrophoretic mn was completed (as indicated by dye front), slides were 
placed in normal saline. 
10- Results: 
Results were read against a dark background in a transmitted light. 
White precipitin arcs were visible in positive samples. 
Sporozoite positivity rate 
This is the percentage of female anophelines of a given species 
caught in nature and found on dissection, to contain sporozoite in salivary 
glands 
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No. found positive for gland infection 
Sporozoite positivity rate = x 100 
Total no. of dissections 
Human Blood Index: 
Human blood Index is the proportion of freshly fed anophelines found to 
contain human blood. Precipitation tests permit specific differentiation of 
human and animal blood. 
No. found positive for human blood 
Human Blood Index = - ,x 100 
Total No. of blood smear analyzed 
Dissection of salivary gland: 
Dissection of salivary glands of female Anopheles mosquitoes was carried 
in following steps: 
1. Anaesthetized mosquitoes were placed on the right side of glass 
slide with a small drop of normal saline, close to the neck. 
2. With the left hand dissecting needle thorax was pressed gently and 
the head was pushed off with the help of another needle in the right 
hand which was placed just behind the head. 
3. The salivary glands usually dragged out attached to the head and 
appear as small, sausage shaped refrectile bodies. 
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4. The glands were separated from the head by cutting with sharp 
blade in a drop of normal saline on the slide. 
5. Glands were covered with small cover slip, tapped gently and 
examined under high magnification (i.e. 40X and 100X objectives). 
Staining of sporozoite positive slides: 
Slides containing the glands, positive with sporozoite, were first fixed 
with a few drop of formol saline solution under cover slip. The formol saline 
consists of one part of formalin (40% formaldehyde) and nine parts of 
normal saline. After the formol saline had completely dried, the cover slip 
was removed with the help of two dissecting needles and area containing 
the glands was marked by glass marking pencil. The formol saline was 
then washed thoroughly by at least three changes of distilled water. For 
staining, three drops of stock solution of Leishman's stain was added to 
the marked area of slides and on the cover slip containing parts of the 
glands. It was diluted by adding seven drops of distilled water. The diluted 
stain was allowed to act for 30 minutes. During this period, the stain was 
slowly agitated with the help of a Pasteur pipette to avoid scum formation. 
The slides were thoroughly washed with repeated changes of distilled 
water till all the stain deposits had been completely removed, when dried 
permanent mounting was done with D. P.X. 
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RESULTS 
Survey for the screening of Anopheline mosquito was carried out 
from 2000-2002 in Aligarh revealed the presence of seven species I.e. An. 
culicifacies, An. subpictus, An. annularis, An. Stephens!, An. vagus. An. 
lindesayi and An. barbirostris (Fig 1-7). Their diagnostic morphological 
features are as follows: 
An. culicifacies: 
• Wing with four dark spots on costa Involving vein I 
• Femur and tibia not speckled 
• Tarsal segments of forelegs with very narrow bands 
• Tips of palpi are white 
• Vein 3 mainly dark 
An. subpictus: 
• Wing with four dark spots on costa involving vein I 
• Femur and tibia not speckled 
• Tarsal segments of forelegs with very nanrow bands 
• Palpi with dark preapical band equal or nearly equal to apical white 
band. 
An. annularis: 
• Wing with four dark spots on costa involving vein I 
• Femur and tibia not speckled 
• Hind tarsi 5,4 and 3 completely white 
• At the bifurcation of vein 5 the area is dark 
• Apical pale band nearly equal to the pre-apical dark band. 
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An. stephensi: 
• Wing with four dark spots on costa involving vein I 
• Femur and tibia speckled 
• Fore legs tarsomeres without broad bands 
• Palpi with 3 white bands and usually speckled. 
An. vagus: 
• Wing with four dark spots on costa involving vein I 
• Femur and tibia not speckled 
• Tarsal segments of fore legs with broad bands 
• Palpi with dark pre apical band not more than Ya of the length of 
apical white band. 
An. lindesayi: 
• Wing with three dark spots on costa involving vein I 
• Palpi all dark. 
• Hind femur with a white band 
An. barbirostris: 
• Wing with three dark spots on costa involving vein I 
• Hind femur without any white band 
• Palpi all dark. 
From Table - I it is evident that the An. culicifacies was the 
predominant species (37.02%) in the area followed by An. subpictus 
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(35.01%), An. annularis (16.07%), An. Stephens! (8.78%) and An. vagus 
(2.68 %). Whereas rest of the anopheline species i.e. An. lindesayi 
(0.21%) and An. bart^irostris (0.19%) were recorded less than one percent 
in Aligarh. (Graph I) 
Monthly prevalence of different anophelines is shown in Table II & 
III. An. culicifacies which was most abundant species showed two peaks, 
one in the month of March and April and other during July, August and 
September (Graph II & lll).They were also recorded in high numbers in 
November. These mosquitoes were recorded in less numbers during 
January and February and May and June. An. subpictus was next in queue 
with its peak in September and October and lowest densities in February 
and March. As for as An. annularis is concerned which was next dominant 
species recorded during the present study showed its peak in September 
and October. This species showed low density in the months of January 
and February. An. Stephens! \Nas on fourth place and found throughout the 
year with its peaks in the month of March and April and then in August and 
' October, which are supposed to be the stable months with low rainfall. An. 
vagus recorded at fifth place which showed fluctuating number throughout 
the year showing slight increase in number during the months of April and 
September. Rest of the species such as An. lindesayi and An. barbirostris 
which showed very low count, generally detected during the post monsoon 
season found up to January. 
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Month wise prevalence showed in Table- II & III indicates that 
population of most of anophelines was quite abundant during post 
monsoon season (i.e. from July to November). During these months 
moderate temperature (26-28°C) and optimum humidity (77-88%) 
prevailed which were ideal for breeding of mosquito and accounted for the ' 
increase in mosquito population. 
Table- IV shows the blood meal analysis of An. culicifacies and An. 
Stephens!. Out of 1259 blood smear analyzed for An. culicifacies, 476 
(37.80%) were found positive for human blood, 396 (31.45%) for bovine 
blood and 387(30.7%) for mixed (Graph IV). Out of 799 blood smears 
analyzed for An. stephensi, 319 (39.92%) were found positive for human 
blood, 270 (33.79%) for bovine blood and 210 (26.28%) for mixed (Graph 
V). Human blood index for An. culicifacies and An. stephensi were 37.80% 
and 39.92%, respectively. 
Table-V shows the result of dissection of glands of three suspected 
anopheline species i.e. An. culicifacies, An. stephensi and An. annularis. 
From 2190 An. culicifacies, 742 An. stephensi and 502 An. annularis 
salivary glands were successfully dissected out and examined for the 
sporozoite positivity (Plate 1). Salivary glands of nine specimens of An. 
culicifacies and 2 specimens of An. stephensi were found to contain 
sporozoites showing positivity rates of 0.41% and 0.26%, respectively. 
While none of the glands of An. annularis showed presence of sporozoite. 
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Fig. 2 An. subpictus 
a Wing with four dark spots on costa involving vein 1 
b Femur and tibia not specified 
c Tarsal segments of forelegs with very nan^ ow bands 
d Palpi with dark preapical band equal or nearly equal to apical 
white band. 
y\ 
FIG.2 
Fig. 3 An. annularis 
a Wing witli four dark spots on costa involving vein I 
b At tine bifurcation of vein 5 tlie area is dark 
c Femur and tibia not speckled 
d Hind tarsi 5,4 and 3 completely white 
e Apical pale band nearly equal to the preapical dark band 
-A 
>C5.3 
Fig. 4 An. Stephens! 
a Wing with four dark spots on costa involving vein 
b Femur and tibia speckled 
c Fore legs tarsomeres without broad bands 
d Palpi with 3 white bands and usually speckeld. 
:t,-—i_ 3 
if 
FIG.4 
Fig. 5 An. vagus 
a Wing with four dark spots on costa involving vein I 
b Fennur and tibia not speckled 
c Tarsal segments of fore legs with broad bands 
d Palpi with dark pre apical band not more than V2 of the length 
of apical white band. 
2 3 
/ \ 
/ • 
Fig. 6 An. lindesayi 
a Wing with three dark spots on costa involving vein 
b Palpi all dark. 
c Hind femur with a white band 
FJGL6 
Fig. 7 An. barbirostris 
a Wing with three dark spots on costs involving vein 
b Hind femur without any white band 
c Palpi all dark. 
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Species 
An. culicifacies 
An. Stephens! 
An. annularis 
An. subplctus 
An. vagus 
An. lindesayi 
An. barbirostris 
Total mosquito 
collected 
6931 
1645 
3010 
6555 
502 
40 
37 
18720 
% 
37.02 
8.78 
16.07 
35.01 
2.68 
0.21 
0.19 
Table I- Percent composition of different species of anophelines in 
Aligarh during 2000- 2002 
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Species 
No. of 
Blood 
Smears 
analyzed 
Numbers 
positive for 
human blood 
Numbers 
positive for 
bovine 
blood 
Mixed HBI 
% 
An. culicifacies 1259 476 (37.80%) 396(31.45%) 387 (30.7%) 37.80 
An. Stephens! 799 319(39.92%) 270 (33.79%) 210(26.28%) ' 39.9 
Table IV- Blood meal analysis results of An. culicifacies and 
An. steptiensi 
Species 
An. culicifacies 
An. stephensi 
An. annularis 
Numbers 
collected 
2899 
787 
800 
Dissected 
glands 
2190 
742 
502 
Positive 
glands 
9 
2 
0 
Sporozoite 
positivity rate j 
0.41% 
0.26% 
0% 
1 
Table V- Results of dissection of anophelines collected from the 
human dwellings 
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Graph 1. Percent composition of different species of anopheline in Aligarh 
during 2000- 2002 
2.68 
0.21 0.19 
An. culicifacies An. Stephens! An.annularis An. subpictus An. vagus 
Different species of anophelines 
An. lindesayi An. barbirostns j 
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Graph 2. Month-wise prevalence of anophelines in Aligarh 
during 2001 
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Graph 3. Month-wise prevalence of anophelines 
in Aligarh during 2002 -^-An. cuiidfacies 
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Graph 4. Blood meal analysis of An. cuUc'rfacies 
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Plate 1 Salivary gland of of An. culicifacies showing sporozoites 
DISCUSSION 
Malaria still continues to be one of the most important vector 
borne diseases of the world causing extensive morbidity and 
mortality in tropics and subtropics. Anopheline vectors play a role in 
the transmission of this disease. Present study was conducted to 
screen all the anopheline species operating in Aligarh. Vectors 
responsible for malaria transmission were incriminated. Sporozoite 
positivity rate and human blood index of vector species were also 
determined. 
Survey carried out during the years 2000-2002 in Aligarh 
revealed the presence of 7 anopheline species. Among these the 
An. cuHcifacies is the predominant species (37.02%) in the area followed 
by An. subpictus (35.01%), An. annularis (16.07%), An. Stephens! (8.78%) 
and An. vagus (2.68 %). Whereas rest of the anopheline species i.e. An. 
lindesayi (0.21%) and An. barbirostris (0.19%) were recorded less than 
one percent in Aligarh. 
In the present study the higher numbers of anophelines were 
recorded from July onwards up to November, which was probably 
because of availability of plenty of breeding sites for the mosquito 
after rains in the preceding months. Moderate temperature (26-
.28°C) and optimum humidity (i.e. 77-88%) during these months 
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were ideal for the breeding of mosquito, might have influenced 
increase in mosquito population which must have contributed 
maximum malaria transmission. Anopheline population decreased 
from December to June, which was because of adverse 
environmental factors, which caused reduction in mosquito 
population. During these months either extreme dry cold or dry hot 
conditions prevail which affect mosquito population adversely either 
by making water bodies unsuitable or very slow for breeding or by 
making them scarce due to of high temperature which even kill the 
mosquito. 
In present study An. culicifacies were found in significant 
numbers throughout the year having low densities in the months of 
January & February and May & June. This species had two peaks 
one in March & April and other in July to September. November also 
showed high density. This suggests that there is a seasonal 
element, which regulates its activity. The present observations 
however, indicate that the most important controlling factor seems 
to be formation of fresh and rain water pools during July & August 
and sometimes in October also as earlier indicated by Bhatia et al. 
(1958a). 
An. annularis was found in relatively low densities from May to 
July and started building up in August onwards upto October 
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supports the assertion of Senior White (1929) who reported this 
species essentially a cold weather mosquito. 
An. Stephens/ showed one peak in March & April and other 
from August to October; therefore, it appears to be largely a spring 
mosquito showing preference for periods having low or no rainfall. 
An. subpictus is known to be a markedly domestic species and was 
the second dominant anopheline collected during present survey. Its 
density started building up in April and rose to its peak in September 
and October but there was a gradual decline in the density from 
November onwards. An. subpictus breeds in very temporary water 
collections and such type of waters collections are found during 
monsoon explains the seasonal trend depicted by this species. 
An. vagus showed very erratic behavior throughout the year and 
was found in fluctuating numbers. During March and April and again 
in September and October they showed little increase in density. 
An. barbirostris and An. lindesayi were found in comparatively less 
numbers. These species were recorded in post monsoon season 
when plenty of breeding sites were available. 
Similar anopheline surveys were conducted by Nagpal et al. 
(1983), Yadav et al. (1989) and Tiwari et al. (1997) in Nainital 
district, Kheda (Gujrat) and Allahabad, respectively. Nagpal et al. 
(1983) recorded 18 anopheline species from six tehsils of Terai 
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(UP.). Among these An. subpictus was most prevalent (29.60%) 
followed by An. culicifacies (26.86%), An. fluviatilis (17.37%), An. 
annularis (10.84%), An. splendidus (8.45%), An. nigem'mus (2.90%) 
and An. aconitus (1.62%). Rest of the anophelines such as An. 
Stephens!, An. vagus, An. barbirostris, An. lindesayi. An. varuna, 
An. umbrosus and An. pallidus were accounted for less then 1 %. 
Yadav et al. (1989) conducted an Intensive anopheline survey 
in Kheda district from 64 villages and found 16 anopheline species. 
Four anophelines namely An. subpictus, An culicifacies. An. 
annularis, An. stephensi were predominant and constituted 99.9% 
of total population and rest of 12 species i.e. An. vagus, An. 
barbirostris. An. theobaldi. An. varuna. An. aconitus. An. fluviatilis. 
An. tesselatus. An. nigerrimus. An. pulciierrimus and An. 
- moghulensis accounted for 0.1%. 
Tiwari et al. (1997) recorded 14 anopheline species in stone 
quarry area of Allahabad. Among these An. subpictus (40.84%) top 
the list followed by An. culicifacies (36.78%) and An. annularis 
(17.03%), which were found in good numbers. Rest of the 
anopheline species such as An. pallidus (4.40%), An.splendidus 
(0.21%), An.aconitus (0.35%), An. stephensi (0.01%), An. vagus 
(0.20%), An. barbirostris (0.9%), An. varuna (0.02%), and An. 
tesselatus (0.15%) were recorded less then one percent. 
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As indicated above Nagpal et al. (1983), Yadav et al. (1989) 
and Tiwari et al. (1997) recorded 18, 16, 14 species in their 
experimental areas while in the present study only 7 anophelines 
species were recorded. Low count of the species recorded in the 
present study was probably because of less experimental area 
coverage. During vector incrimination in the present study nine 
An. culicifacies and two An. Stephens! were found positive for 
sporozoites. Sporozoite positivity rate for An. culicifacies and An. 
Stephens! v^ere 0.41% and 0.26%, respectively. Human blood index 
for An. culicifacies and An. Stephens! was recorded 37.80% and 
39.5%, respectively. Sporozoite positivity rate was low because 
mosquito were collected randomly from different localities of Aligarh 
and only a fraction of captured An. culicifacies and An. stephensi 
were infected. Out of infected mosquito only a few of them might 
have completed sporogony at the time of dissection. Since 
sporozoites reach salivary glands only after 10-12 days, probability 
of finding sporozoites at the time of dissection becomes very low. 
Low HBI further minimized the chance of infectivity. Low HBI also 
indicates their moderate endophilic nature. Both the species have 
slightly higher preference for human blood as compared to bovine. 
Though An. culicifacies found in good numbers, only 37.80% of 
them show positivity for human blood. A fair population of An. 
60 
culicifacies was found to be exophagic and exophilic in nature and 
feeding on cattle as earlier reported by Kaira (1978) and Nagpal and 
Sharma (1985) who also observed exophilic and exophagic 
population of An. culicifacies from Tamil Nadu and Orissa. 
Sporozoite positivity rate of 0.41% and 0.26% are low count 
for malaria transmission but it is not very low for a place like Aligarh, 
which is not a high transmission region. 0.26% sporozoite positivity 
rate for An. stephensi v^hich was recorded during present study is in 
agreement with Siddons (1946), Negoy and Sen (1962) and 
Choudhury and Sen (1987) who recorded 0.57%, 0.52% and 0.10% 
sporozoite positivity rate from Kolkata. Our findings of incriminating 
An. culicifacies as malaria vector in campus of Aligarh showing 
transmission rate of 0.41% is in agreement with Nagpal and Sharma 
(1986) who had reported slightly high positivity of 1.33% for An. 
culicifacies in comparatively higher transmission region of Orissa. 
Bhatnagar et al. (1982), Das and Baruah (1985), Dutta and Baruah 
(1987) and Wajihullah et al. (1992) incriminated An. minimus in 
Nagaland, Mizoram, Arunachal Pradesh and Assam, respectively. 
The sporozoite positivity rate observed by these workers ranged 
from 1.4 to 8.3%), which are comparatively much higher than 
reported in the present study. It is probably because of the reason 
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that vector involved in these studies was An. minimus which is 
highly anthropholic species showing human blood index of 90% and 
is operating in high transmission region (Wajihullah et al. 1992). 
Our finding of sporozoite positivity rate (0.41%) for An. 
culicifacies in of Aligarh is in corroboration with the findings of 
Mayne (1928), Covell and Jaswant (1943), Bhatia et a/.(1958); 
Chaudhury et al. (1983), Annual report MRC (1983-84). Ansari et 
a/.(1986) and Prasad and Sharma (1990) who had reported 
sporozoite positivity rates of 0.148%, 0.196%, 0.157%, 0.189%, 
0.489%, 0.832%, 0.490%, and 2.89% from Saharanpur, Delhi, 
Khurja, Gadarpur, Ghaziabad, villages of Bareilly and Meerut 
The present study which was conducted in low transmission 
region of Aligarh, by enlarge have rural or suburban types of 
localities where An. culicifacies is acting as a principal vector is in 
conformity with the findings of Nagpal and Sharma (1986) who 
reported An. culicifacies as principal vector in Orissa. Incrimination 
of An. culicifacies by above workers in the villages of plains of U P 
and plains, coastal and even urban areas of Orissa established its 
role in malaria transmission. While An. stephensi, which is an 
established vector for urban areas, was also incriminated in the 
present study from thickly populated area of Aligarh probably 
supports transmission of malaria in Aligarh particularly in the hot 
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summer in urban type of locality as earlier observed by Negoy and 
Sen (1962) and Choudhury and Sen (1987) in Calcutta. 
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PartB 
Relapse and Resistance 
patterns in P. vivax and 
P, falciparum 
PART B Relapse and Resistance patterns in P. vivax 
and P. falciparum 
MATERIALS AND METHODS 
Present study is based on the malaria cases enrolled in Jawaharlal 
Nehru Medical College and a few other hospitals and clinics of Aligarh 
during the years 2001, 2002 and 2003. Blood smear were prepared from 
patients who attended hospitals and clinics, complained for fever and 
headache and were suspected of malaria. Thin and thick blood smears of 
patients were prepared by finger prick, stained with J.S.B. and Giemsa 
stains and microscopically examined under an oil immersion lens to see 
the positivity for malaria infection. 
Preparation and fixation of blood smear: 
Good quality clean glass slides of about 1.2 mm thickness were 
used for making smears. Greasy sides were first cleaned by boiling with 
detergents, subsequently scrubbed and washed thoroughly in running 
water so as to remove all traces of detergents and grease. For making 
blood smear the tip of middle or ring finger of the left hand was cleaned 
with spirit swab and allowed to dry completely before pricking. Two drops 
of blood were placed on two slides one for thick smear and other for thin. 
The thick smear was made in such a way that the edge of smear remains 
approximately 1.0 cm away from the edge of the slide. The distance 
between the edge of thick and thin smear was about 0.75 cm. Only thin 
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smear were fixed with methyl alcohol. After drying, slides were stained with 
Giemsa and JSB as described by Singh (1956). 
Preparation of staining solution: 
0) Preparation of JSB-1 solution: 
For preparation of JSB-1 solution 0.5 mg of methylene blue was 
dissolved thoroughly in 500 ml distilled water in flask. 3 ml of 1% sulphuric 
acid was added drop by drop to the solution and then mixed with 0.5 gm of 
potassium dichromate. Addition of potassium dichromate led to the 
formation of some precipitate and at this step 3.5 gm of disodium hydrogen 
phosphate dihydrate was added. The mixture was boiled for half an hour. 
The stain was allowed to cool at room temperature and was ready for use 
as JSB-1 solution. This solution when used after maturation of 2-3 weel<s 
gave better results. 
(I!) Preparation of JSB-1 solution: 
It was prepared by dissolving 1 gm of water soluble eosine in 5QO ml 
of distilled water. A freshly prepared eosine solution, although can be used 
immediately, may not yield as satisfactory result as the one which has 
turned deep red after some storage. 
(ill) Preparation of buffer water: 
This was prepared by dissolving disodium hydrogen phosphate 
dehydrate (0.22) and potassium acid phosphate (0.74 gm) in 1000 ml 
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distilled water. To maintain initial pH buffered water was kept in glass 
bottles. 
Staining: 
Slide staining was done with JSB in following steps: 
(a) 2-3 dips in JSB-II 
(b) Washing 10 times in buffer water 
(c) A dip of 45 seconds in JSB-I 
(d) Washing 10 times in buffer water 
(e) Drying thoroughly before examination 
A good number of slides were also stained with Giemsa. For staining 
with Giemsa, thin smears were first fixed in methanol and dried in air by 
waving hand while thick films were allowed to dry (not fixed), and 
dehaemoglobinized prior to putting it in the stain. Dried slides were 
transferred in Giemsa stain for 3-5 minutes, then passed on to the same 
stain diluted with distilled water (1:1) and allowed to stain for 15-20 
minutes. Finally slides were washed thoroughly under tap water and dried. 
Examination of slides: 
Slides were examined under the microscope with 10X and 40X 
objectives to see the positivity for malaria parasite. Positive slides were 
then thoroughly examined under an oil immersion lens (100X) to ascertain 
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the type of infection (i. e. Plasmodium vivax, Plasmodium falciparum or 
mixed type) 
From malaria positive cases, monthly prevalence of Plasmodium 
vivax and Plasmodium falcipamm infections were recorded. Month-wise 
slide positivity rates (SPR) and slide falciparum rates (SFR) were worked 
out for the years 2001, 2002 and 2003. Resistant and relapse cases were 
also observed in Plasmodium falciparum and Plasmodium vivax infections, 
respectively. 
Slide Positivity Rate (SPR): It is defined as, the number of blood smears 
found positive for malaria parasite per 100 blood smears examined. 
No. of blood smears positive for malaria 
Slide Positivity Rate = x 100 
No. of blood smear examined 
Slide Falciparum Rate: It is defined as, the number of blood smears 
found positive for Plasmodium falciparum per 100 blood smears examined. 
No. of blood smears positive for P. falciparum 
Slide Falciparum Rate= x 100 
No. of blood smear examined 
Relapse In Plasmodium vivax infections: 
For the study of relapse in Plasmodium vivax, one group of patients 
was treated by giving 1500 mg chloroquine base in divided doses (i. e. 600 
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mg on day 0, 300 mg after 8 hours followed by 300 mg daily for 2 days). 
The dose of child was adjusted according to his/her body weight. While 
patients in other group were administered 1500 mg chloroquine in the 
similar manner followed by 15 mg primaquine daily for 5 days and then 
followed up carefully. To determine the pattem of relapse in Plasmodium 
vivax each patient was identified individually by name, address and 
subsequent treatment. On reporting back blood smears were prepared 
from the patient and examined microscopically for the presence of malaria 
parasite and entered against his/her name. 
The following criteria were used in classifying the patients into 
primary cases and non-relapse and relapse categories in the present 
study. Patient reporting for the first time (having no history of malaria) with 
acute illness and showing symptoms such as high fever, severe headache, 
loss of appetite, occasional vomiting and microscopic evidence of 
Plasmodium vivax infection were considered as primary cases. Some 
patients in this group who had no clinical symptoms of malaria or 
parasitological evidence of Plasmodium vivax infection following their 
primary infection during the entire period was considered as non-relapse 
cases. Those patients who reported back to the clinic within one month to 
one year with renewed clinical symptom (mild) along with a periodic 
alternate day fever (not observed in the primary cases) and found to be 
microscopically positive for Plasmodium vivax infection were considered as 
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relapse cases. After medication if patient again suffered from malaria 
within 3 months with more regular paroxysm, he/she was treated as a case 
of short term relapse. But if it happened beyond 3 months then the case 
was considered as long term relapse. Cases of Plasmodium vivax who did 
not respond to 1500 mg of chloroquine and 75 mg primaquine was 
recorded as chloroquine resistant cases. 
Drug resistance in Plasmodium falciparum infections: 
For drug resistance, patients who were positive for Plasmodium 
falciparum infections were given 1500 mg chloroquine base in divided 
doses (i. e. 600 mg on day 0, 300 mg after 8 hours followed by 300 mg 
daily for 2 days). The dose of child was adjusted according to his/her body 
weight. Blood films of those patients who reported back with fever within 4 
weeks of treatment were examined for Plasmodium falciparum infection. If 
found positive, such cases were recorded as chloroquine resistant cases. 
Level of resistance (i.e. Rl, Rll, Rill) was ascertained on the basis of late 
and early recrudescence. 
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RESULTS 
Tables VI, VII and VIII show month wise slide positivity rates and 
slide falciparum rates for the years 2001, 2002 and 2003 for Plasmodium 
vivax and Plasmodium falciparum infections observed in Aligarh. These 
tables also provide information on seasonal fluctuations of aforesaid 
species. Plasmodium vivax infection was predominant and was recorded in 
all months of the year, with almost similar seasonal patterns during the 3 
successive years. Plasmodium vivax showed a gradual increasing trend 
from July onwards reaching a peak in September soon after the rainy 
season, and then showed a decline in December which continued upto 
June. Plasmodium falciparum infections started Increasing in July-August 
and showed a peak in September and October and then decline November 
onwards with the on set of winter and continued to decline till July. (Graph 
6, 7 and 8) 
During 2001 out of 1473 slides examined, 487 were found positive 
for malaria of which 311 belonged to Plasmodium vivax and 176 to 
Plasmodium falciparum. In 2002 a total of 1369 slides were examined, out 
of which 498 were found positive for malaria of which 329 belonged to 
Plasmodium vivax and 169 to Plasmodium falciparum. In 2003 a total of 
1428 slides were examined for malaria infection, out of which 580 were 
found positive. Slides showing positivity for Plasmodium vivax and 
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Plasmodium falciparum were 363 and 217, respectively (Plates 2 & 3). 
During 2001, 2002 and 2003 overall percentage of Plasmodium vivax and 
Plasmodium falciparum were 63.86, 66.06, 62.58 and 36.13, 33.93 and 
37.41, respectively. (Table IX & Graph 9) 
It was observed that malaria transmission was least from January to 
April. During the months of May, June and July transmission was low with 
slight fluctuating figures for the years 2001, 2002 and 2003 which was in 
accordance with the commencement of pre-monsoon shower that 
contributed slightly increased or decreased transmission rate in proceeding 
months. Increased rate of transmission was recorded July onwards, 
- reaching a peak soon after rains in September and October followed by a 
sharp decline to a low level in December. During peak transmission , 
season mean temperature and relative humidity ranged somewhere 
around 26-28"'C and 77 to 88%. 
Plasmodium vivax and Plasmodium falciparum showed almost 
similar transmission pattern during the years 2001, 2002 and 2003 having 
mean SPR 27.69%, 27.52% and 31.95%, respectively. A considerable 
degree of fluctuation was observed during peak transmission season (i.e. 
September and October) when SPR was comparatively high and ranged 
61.76 to 50.14%. During this peak period slide falciparum rate was also 
high ranging from 11.46 - 23.94% which is parallel to SPR (Graph 10, 11 
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and 12). During this period vector density was also high which might have 
resulted in high transmission rate and increased SPR and SFR. 
Table X shows year wise analysis of Plasmodium vivax, non 
relapsing versus relapsing patients and relapse rates with different follow 
up duration. In 2001 a total of 144 patients were observed of which 122 did 
not have any further relapse whereas 22 had relapses in two year follow 
up study having a relapse rate of 15.2%. Similarly for the year 2002 and 
2003 the relapse rates were 19.1 and 17.1 % respectively. Short term 
relapses were more then the long term in the ratio of about 4:1. In 2001, 
2002 and 2003 short and long term relapses were recorded as 11.1 and 
4.1, 15.7 and 3.3 and 13.2 and 3.92%, respectively. Above percentage of 
relapse were recorded in patients who were given 1500 mg chloroquine 
-base in divided doses (i.e. 600 mg on day 0, 300 mg after 8 hours 
followed by 300 mg daily for 2 days). 88 patients who were administered 
with 1500 mg chloroquine and 75 mg primaquine in divided doses also 
showed resistance in 4.5 % cases. 
Table XI shows the frequency distributions of 124,148 and 157 
patients showing resistance against chloroquine in 9.6, 10.8 and 11.4% 
cases after getting 1500 mg chloroquine base in divided doses (i.e. 600 
mg on day 0, 300 mg after 8 hours followed by 300 mg daily for 2 days). 
Out of 124 patients studied during 2001,112 were susceptible, whereas 12 
patients showed resistance against chloroquine. The level of resistance 
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was Rl and Rll type in 6.4 and 3.2 % cases. In 2002 out of 148 patients 
132 were susceptible while 16 showed resistance out of which 6.7% were 
of Rl type and 4.1% were of Rll type. Similarly in the year 2003 out of 157 
patients observed 139 were found susceptible and 18 showed resistance 
out of which 8.2% were of Rl type and 3.2% were of Rll type. 
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Month 
Jan 
Feb 
March 
Apr 
May 
June 
July 
Aug 
Sept 
Oct 
Nov 
Dec 
BSE 
27 
32 
47 
54 
62 
55 
74 
135 
382 
351 
157 
97 
Total 
cases 
8 
8 
11 
13 
12 
U 
27 
28 
170 
129 
50 
20 
P. vivax 
6 
5 
7 
8 
8 
7 
21 
19 
108 
78 
32 
12 
P. 
falciparum 
2 
3 
4 
5 
4 
4 
6 
9 
62 
51 
18 
8 
SPR 
29.62 
25.00 
23.40 
24,07 
19 35 
20.00 
36.48 
20.74 
44.50 
36.75 
31.84 
20.61 
SFR 
7.40 
9.35 
8.51 
9.25 
6 45 
7.27 
8.10 
6.66 
16.23 
14.52 
11.46 
8.24 
Table VI. Prevalence of malaria showing parasite distribution, SPR 
and SFR during year 2001 
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Month 
Jan 
Feb 
Mar 
Apr 
May 
June 
July 
Aug 
Sept 
Oct 
Nov 
Dec 
BSE 
41 
53 
39 
65 
47 
67 
89 
143 
247 
293 
182 
103 
Total 
cases 
11 
13 
11 
12 
12 
17 
28 
44 
136 
138 
62 
14 
P. vivax 
8 
9 
9 
8 
9 
11 
21 
31 
94 
81 
41 
7 
R falciparum SPR 
3 1 26.95 
4 
2 
4 
3 
6 
7 
13 
42 
57 
21 
7 
24.52 
28.20 
18.46 
25.53 
25.37 
31.46 
30.76 
55.06 
47.09 
34.06 
13.59 
SFR 
7.31 
7.54 
5.12 
6.15 
6.38 
8.95 
7.86 
9.09 
17.00 
19.45 
11.53 
6.79 
Table VII. Prevalence of malaria showing parasite distribution, SPR 
and SFR during year 2002 
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Month 
Jan 
Feb 
Mar 
Apr 
May 
June 
July 
Aug 
Sept 
Oct 
Nov 
Dec 
BSE 
37 
31 
51 
72 
61 
57 
95 
149 
218 
347 
213 
97 
Total 
cases 
8 
11 
10 
16 
14 
12 
21 
53 
134 
174 
106 
21 
P. vivax 
6 
9 
7 
11 
10 
9 
14 
39 
92 
102 
55 
9 
P. falciparum 
2 
2 
3 
5 
4 
3 
7 
14 
42 
72 
51 
12 
1 
SPR 
21.62 
35.48 
19.60 
SFR 
5.40 
6.45 
5.88 
22.2 1 6.94 
22.95 
21.05 
22.10 
35.5 
61.46 
50.14 
49.76 
6.55 
5.26 
7.36 
9.39 
19.26 
20.17 
23.94 
21.64 j 12.37 
Table VIII, Prevalence of malaria showing parasite distribution, SPR 
and SFR during year 2003 
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Year 
2001 
2002 
2003 
BSE 
1473 
1369 
1428 
Total 
Positive 
Cases 
487 
498 
580 
P. vivax 
311(63.86%) 
329(66.06%) 
363(62.58%) 
P. 
falciparum 
176(36.13%) 
169(33.93%) 
217(37.41%) 
Table IX. Prevalence of malaria P. wVaxand P. falciparum Infections 
during 2001-2003 
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Year 
2001 
2002 
2003 
2003 
Total No. 
Patients 
Observed 
144 
178 
204 
88« 
Non 
Relapsing 
Patients 
122 
144 
169 
84 
Relapsing 
Patients 
22 
34 
35 
4 
Short 
Term 
Relapse 
16 
28 
27 
4 
Long 
Term 
Relapse 
6 
6 
8 
Relapse 
Rate 
15.2 
19.1 
17.1 
4.5 
Follow -
up Year 
2 
1 
1 
Table X. Relapse cases in P. v/Vax infection 
"Patients given 75 mg primaquine base following chtoroquine 
treatment 
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Years 
2001 
2002 
2003 
No. of 
P.falciparum 
patients 
observed 
124 
148 
157 
Non-
Resistant 
Patients 
112 
132 
139 
Resistant patients 
Total 
12 
16 
18 
Rl 
8 
10 
13 
Rll I Rill 
4 
6 
5 
Resistance rate 
Total 
9.6 
10.8 
11.4 
Rl 
6.45 
6.75 
1 8.2 
1 
Rll RUI 
3.2 
4 
I 3.2 , -
Table XI. Chloroquine resistant cases in Plasmodium falciparum 
infection 
79 
60 
40-
20 
Graph 6. Total malaria cases with distribution of P.vh/ax and 
P.falciparum infections during 2001 
(0 
w 
10 
u 
o o 
c 
s 
o 
180 • 
160" 
140-
120 • 
100-
80-
1 Total positive cases 
—•—P.Mxav 
—A—P.falciparum 
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec 
Months 
80 
Graph 7. Total malaria cases with distribution of P.vivax and 
P.falciparum infections during 2002 
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Graph 8. Total malaria cases with distribution of P.vivax and 
P.faldparum infections during 2003 
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Graph 9. Prevalence of malaria showing percentage of 
P. vivax and P.falciparum during 2001-2003 
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Graph 10. Prevalence of malaria showing SPR and SFR during 
2001 
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Graph 11. Prevalence of malaria showing SPR and SFR during 2002 
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Graph 12. Prevalence of malaria showing SPR and SFR 
during 2003 
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Plate 2 Showing different stages of 
Plasmodium vivax 
le 
Plate 3 Showing different stages of 
Plasmodium falciparum 
DISCUSSION 
Blood smears of patients attending hospitals and clinics of 
Aligarh showing symptoms such as high fever, severe headache, 
loss of appetite and occasional vomiting were examined 
microscopically for Plasmodium vivax and Plasmodium falciparum 
infections. Resistant and relapse cases were observed and followed 
up in Plasmodium falciparum and Plasmodium vivax infections, 
respectively. 
In the present study peak transmission of malaria during the 
months of September and October which was recorded during the 
years 2001, 2002 and 2003 was probably because of the availability 
of plenty of water bodies, supporting breeding of vector species 
after rains in preceding months. Moderate temperature (i.e.26 to 
28°C) and optimum humidity (i.e. 77 to 88%) during these months 
which were ideal for the mosquito breeding might have influenced 
increase in vector population which must have contributed 
maximum transmission as earlier observed by Adak et al. (1998) in 
Delhi. Increased transmission of malaria was also recorded during 
peak season in Assam in areas having streams where vector 
species which happens to be An. minimus was in abundance 
(Wajihullah et al. 1992 and Jana-Kara et al. 1995). Whereas least 
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present study was because of adverse environmental factors v\/hich 
caused reduction in number of vector species. During these months 
either extreme dry cold or dry heat conditions prevail vy/hich affect 
vectors adversely either by making water bodies unsuitable or very 
slow for the breeding or by making them scarce as a result of high 
temperature which even kill the vector. 
Percentage for Plasmodium vivax during years 2001, 2002 
and 2003 was 63.44, 66.06 and 62.58 while for Plasmodium 
falciparum it was 36.55, 33.93 and 37.41. This indicates decrease in 
Plasmodium vivax and an increase in Plasmodium falciparum 
infection. Development of resistance against routine curative drug 
(i.e. chloroquine) might have been one of the reasons for this 
increase in Plasmodium falciparum. Slide falciparum rate (SFR) was 
considerably high during peak transmission period as well as in 
colder months even when transmission rate is low. It is difficult to 
draw exact conclusion but it seems that development of 
Plasmodium falciparum is supported by the vector species more 
readily as compared to P. vivax, may be it is a particular strain of 
some vector species which emerges in good number in winters and 
contributed for raised falciparum malaria. Another probable 
explanation may be this that complicated cases are generally 
referred to medical college and a few of them happens to be 
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falciparum malaria, might have contributed to raise number of 
cases. Since we have collected maximum cases from medical 
college, SFR obtained in the present study is bit high. In contrast 
Plasmodium vivax cases are generally treated outside easily cured 
and therefore are not on record, hence its transmission rate, which 
is observed during this study is proportionately low. 
In the present study 9.6, 10.8 and 11.4 % patients suffering 
from falciparum malaria showed resistance by showing 
recrudescence around first and second week following chloroquine 
treatment during 2001, 2002 and 2003. Sharma (1999) reported 
30% resistant cases in high transmission zone in India. Many other 
reports are available in India and abroad which show increasing 
trend of drug resistance. Ghosh et al. (1992) observed 25% 
chloroquine resistant cases in Orissa. Shah et al. (1997) reported 
chloroquine resistant cases in Pakistan and Afghanistan. 
Mharakurwas et al. (1997) reported resistance in as much as 52% 
patients following chloroquine treatment. Bojang et al. (1998) 
reported failure of chloroquine in Gambian children. In present study 
less percentage of resistant cases were recorded which might be 
because of the reason that study was conducted In low transmission 
region where Plasmodium falciparum infection is proportionately 
less. 
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A very remarkable observation was made during the present 
study that 3 patients having Plasmodium vivax infection showed 
resistance against chloroquine. Similar observation regarding 
resistance of Plasmodium vivax against chloroquine was made by 
Baird et al. (1997). In another study Marler Than et al. (1995) 
recorded recrudescence between 3 and 14 days following 
chloroquine and primaquine treatment which is in corroboration 
with the present finding where chloroquine and primaquine did not 
respond in few cases. 
Relapse rate in Plasmodium vivax during the year 2001, 2002 
and 2003 following the administration of 1500 mg chloroquine base 
were 15.2%, 19.1% and 17.1%, respectively. Short-term relapses 
were more as compared to the long term relapses, which were 11.1, 
15.7, 13.23% and 4.1, 3.3, 3.92%. But relapse rate was quite low 
(I.e. 4.5%) and was of short term type, when 75 mg primaquine 
base was also administered following chloroquine treatment. This 
Indicates that both chloroquine and primaquine were not fully 
effective even when they were administered In a total curative dose 
to the patients suffering from vivax malaria. Similar observations 
were made by Srivastava ef al. (1996) who recorded more short-
term relapses and a few long-term relapses after administration of 
600 mg chloroquine, Is in accordance of our finding where more 
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short-term relapses recorded. Adak et al. (1998) recorded 23-44 % 
relapsing cases within a period of 5 years study after giving 900 mg 
chloroquine in 2 doses (600 mg + 300 mg). Smoak (1997) observed 
relapses in 43% Somalian soldiers who received standard dose of 
primaquine. In these studies relapse rates were high as compared 
to our findings. It may be because of the reason that anti relapse 
drug, primaquine was not administered by Adak et al. while in case 
of Smoak's study, may be strain of P. vivax was more tolerant to 
anti relapse drug, primaquine and did not respond to it in a fairly 
good number of cases. 
Regarding the interpretation of the results, one may disagree 
with the differentiation of primary attack versus relapse or 
reinfection, particularly during peak transmission season. However, 
in the absence of any clinical or parasitological marker, the following 
observations are considered as relevant. In the present study, 
malaria cases detected between December and June (the 
supposed non- transmission season) could be grouped in three 
categories. 
I. Infections acquired in the previous transmission season i.e. 
between July and November but remained undetected and thus 
untreated. 
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II. Infections acquired during the previous transn^iission season that 
were detected, treated and subsequently reappeared (relapse). 
III. Infections acquired during the previous transmission season that 
become clinically and parasitologically positive after a prolonged 
period (delayed primary attack). 
Although the reinfection, particularly during the main 
transmission season could not be ruled out, real transmission from 
December to June is probably occasional and at a very low level, if 
supposed non- transmission period with a definite history of malaria 
were considered to be relapse rather than reinfections, whereas 
-those detected with a history of malaria were considered delayed 
primary attacks. However, some uncertainty still exists regarding the 
possibility of reinfection during the supposed non transmission 
season, which probably will persist until some diagnostic tool is 
developed that can distinguish the primary attack and subsequent 
relapse from reinfection. 
It is quite evident from the duration of follow up study (1-2 
years) that the average resistance rate for the year 2001 was 9.6, 
2002 was 10.8 and for the year 2003 was 11.4. The relapse rates 
for the years 2001, 2002 and 2003 were 15.2, 19.1 and 17.1, 
respectively. Therefore the present drug policy of National Malaria 
Eradication Programme for the administration of chloroquine in 
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p. falciparum as the first line curative drug and primaquine 15 mg of 
base, once a day for five consecutive days as anti relapse drug for 
the radical cure of P. vivax infection warrants its reconsideration. 
The mechanism of long survival of Plasmodium vivax during 
non-transmission months through primary long incubation and 
relapses actually ensures transmission in the next season through 
the existence of a reservoir of Plasmodium vivax. It is assumed that 
the primary long and late relapse mechanism of Plasmodium vivax 
might have evolved to survive into the next transmission season 
and be dormant to avoid the host immune response. 
In the view of this information, it is suggested that the 
frequency distribution/ratios of different parasite forms responsible 
- for different relapse patterns should be determined in different P. 
vivax ecosystems with reference to space and time, which are 
probably not constant and likely to be time dependent. In addition, 
the degree to which these parasites sub populations interact with 
each other will no doubt have an impact on the maintenance of 
genetic diversity and regulation of the parasite population as a 
whole. However, in the absence of parasitological and clinical 
markers, it may be difficult to characterize these forms; perhaps 
amplification of specific DNA sequences by the polymerase chain 
reaction using specific oligonucleotide probes from different 
parasites isolates of relapsing and non-relapsing patients could be 
used to analyse the genetic diversity of the P. vivax population and 
correlate this with epidemiological findings. Therefore there is a 
strong need for integrated laboratory and fields studies as well as 
the use of mathematical models to interpret the complex 
transmission dynamics of P. vivax and P. falciparum so that 
appropriate malaria control strategies, including chemotherapeutic 
measures can be devised to prevent relapse and resistance 
problems in P. vivax and P. falciparum. 
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Part C 
DHFR mutation in P. 
vivax and P, falciparum 
PART C DHFR mutation in P. vivax and P. falciparum 
MATERIALS AND METHODS 
Parasite Collection: 
Present study is based on the malaria cases enrolled in Jawaharlal 
Nehru Medical College and a few other hospitals and clinics of Aligarh 
during 2003-2004. Blood smears were prepared from patients who 
complained for fever and headache and were suspected for malaria. Thin 
and thick blood smears were prepared by finger prick, stained with J.S.B 
and Giemsa stains and microscopically examined under an oil immersion 
lense to see the positivity for malaria infection. Patients were treated with 
antimalarial drugs according to the National Drug Policy of India. Briefly the 
vivax malaria patients were treated with a single dose of Chloroquine (10 
mg/ Kg body weight) followed by primaquine 0.25 mg/kg body weight per 
day for 5 days. The falciparum malaria patients were treated with a similar 
dose of chloroquine but a single dose of primaquine (0.75 mg/kg body 
weight). 100-200 pi of heparinized blood was collected from malaria 
parasite positive patients. Informed consent was obtained from the patients 
prior to blood collection, according to institutional ethical guidelines. 
P. vivax and P. falciparum infected blood samples were used for the dhfr 
mutation analysis. 
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Extraction of Parasite DNA: 
Parasite DNA was extracted from the blood of P. vivax and P. 
falciparum patients using AccuPrep Genomic DNA extraction kit (Bioneer 
Corporation, Korea) according to tiie manufacurer's instructions. The DNA 
was eluted in Tris-EDTA buffer (pH 8.0) and an aliquot was used for PCR . 
amplification. 
Extraction of Parasite DNA: 
1. 20 |jl of proteinase K was added to a clean 1.5 ml tube. 
2. 200 | j | of whole blood was added to the tube containing proteinase K 
3. 200 pi of binding buffer (GC) was added to the sample and mixed 
immediately by vortex mixer. Sample was resuspended completely to 
achieve the maximum lysis efficiency. 
4. Incubation was done at 60 "C for 10 minute. 
5. 100 pi of Isopropanol was added and mixed well by pippetting. Tube 
was briefly spin down to get the drops clinging under the lid. 
6. Lysate was carefully transferred into the upper reservoir of the binding 
column tube without wetting the rim. 
7. Tube was closed and centrifuged at 8,000 rpm for 1 minute. Each 
binding column tube was closed to avoid aerosol formation during 
centrifugation. If the lysate has not completely passed through the 
column after centrifugation.lt was reapted again at a higher speed 
(>10000 rpm) until the binding column tube is empty. 
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8. After centrifugation, tube was opened and column tube was 
transferred to a new 2 ml tube for filtration. 
9. 500 |jl of washing buffer 1(w1) was added without wetting the rim. 
Tube was closed and centrifuged at 8,000 rpm for 1 minute. 
10. Tube was opened and solution was poured from the 2 ml tube into a 
disposable bottle 
11. 500 |jl of washing buffer 2 (W2) was carefully added without wetting 
the rim, then the tube was closed and centrifuged at 8,000 rpm for 1 
minute. 
12. Contents were centrifuged once more at 12,000 rpm for 1 minute to 
completely remove ethanol, and check that there is no droplet clinging 
to the bottom of binding column tube. 
13. Now binding column tube was transferred to a new 1.5 ml tube. For 
elution 200 pi of elution buffer (EL or nuclease free water) was added 
to binding column tube, and waited for at least 1 minute at room 
temperature (15 -25 °C) until elution buffer was completely absorbed 
into the glass fiber of binding column tube. 
14. Contents were again centrifuged at 8,000 rpm for 1 minute to elute. 
The eluted genomic DNA is stable and can be used directly, or stored 
at 4 "C for later analysis. For long term DNA storage it must be stored 
at -20 °C, because DNA stored in water is subject to acid hydrolysis. 
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Amplification of pfd/ifr gene: 
The P. falcipamm 720-bp fragment of the dhfrgene was amplified by 
using primers AMP-1(5^-TTT ATA TTT TCT CCT TTT TA-3') and AMP-
2(5XAT TTT ATT ATT CGT TTT CT-3^).The cycling parameters used 
were as follows: denaturation at 94°C for 30s, annealing at 45°C for 45s, 
and extension at 72°C for 45s. A total of 45 cycles were carried out. A 
mutation-specific nested PCR was performed with this primary PCR 
- product to detect the nucleotides at five dhfr codons; codons 16, 51, 59, 
108 and 164. Two separate sets of PCRs were carried out for each codon, 
one for the wild-type allele and one for the mutant allele. In the case of 
codon 108, three reactions were earned out: one for the wild-type and two 
for mutant alleles. The primers and their sequences were as follows: DIA-
1,5'GAA TCC TTT CCC AGC-3'; DIA-9, 5'-GAA TCC TTT CCC AGG-3'; 
DIA12, 5'-GGA ATG CTT TCC CAG T-3^ SP-1,5'ATG ATG GAA CAA 
GTC TGC GAC-3'; FR-59W, 5'ATG TTG TAA CTG CAC A-3'; FR-59M, 
5'-ATG TTG TAA CTG CAC G-3^ FR-51W, 5'-TTA CCA TGG AAA TGT 
AA-3^ FR-51M, 5'TTA CCA TGG AAA TGT AT-3 ; SP-2, 5^-ACA TTT TAT 
TAT TCG TTT TC-3^; DIA-13, 5 -^CAA CGG AAC CTC CTA T-3^; DIA-14, 
5 -^CAA CGC AAC CTC CTA A-3\ DIA-15, 5 -^TTT ATG CCA TAT GTG T-
3'; DIA-16, 5'-TTA TGC CAT ATG TGC-3^ and SP-3, 5^-TTT AAT TTC 
CCA AGT AAA AC-3'(4,9,12,28,34). Only 15 cycles of the nested PCR 
were carried out. The cycling parameters for the different sets of primers 
98 
were as follows. For detection of the nucleotide at codon 16 with primers 
specific for either the wild type (primers DIA-16 and SP-2) or the mutant 
(primers DIA-15 and SP-3), denaturation was carried out at 94°C for 30 s, 
annealing was carried out at 50°C for 30 s, and extension was carried out 
at 72°C for 45 s. For detection of the nucleotide at codon 51 with primers 
specific for the wild-type sequence (primers FR-51W and SP-2) or the 
mutant sequence (primers FR-51M and Sp-2), denaturation was carried 
out at 92°C for 30 second. For detection of the nucleotide at codon 59 with 
primers specific for the wild-type sequence (primers FR-59W and SP-1) or 
the mutant sequence (primers FR-59M and SP-1), denaturation was 
carried out at 92°C, annealing was carried out at 54°C for 30 second, and 
extension was canried out at 72°C for 30 second. For detecton of the 
nucleotide at108 with primers specific for the wild-type sequence (primers 
DIA-3 and SP-1) or the mutant sequence (primers DIA-9 and SP-1 for Thr 
or primers DIA-12 and SP-1 for Asn), denaturation was carried out at 94°C, 
annealing was done at 55°C for 30 second, and extension was canried out 
at 74°C for 30 second. For the detection of the nucleotide at codon 164 
with primers specific for the wild type sequence (primers DIA-13 and SP-1) 
or the mutant specific (primers DIA-14 and SP -1), denaturation was 
carried out at 94°C for 30 second, annealing was done at 54°C for 30 
second, and extension was carried out at 72°C for 45 second. The PCR 
products were purified and subjected to nucleotide sequencing using an 
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ABI big dye terminator ready reaction kit, version 3.1 and ABI prism 310 
genetic analyzer (PE Applied Biosystems, California). 
Amplification of pvdhfr gene: 
A 1,014-bp fragment of P. vivax dhfr-ts gene was amplified using 
primers PvDA (5'- ACCGCACCAGTTCCTAC-3') (forward) and PvDB (5'-
TGTTAAAGCTGAAGTACACGAG-3') (reverse) with following cycling 
parameters: a 10 minute initial denaturation step at 94°C was followed by 
35 cycles with a 30 second denaturation step at 94X, a 1 minute 
annealing step at 58 °C, a 1 minute extension step at 72°C and a final 10 
minute extension step at 72 °C. This primary PCR product was diluted 10 
times and used as a DNA template for nested PCR to amplify the 784-bp 
-region, which covers the entire DHFR domain. Primers PvDF (5'-
ATGGAGGACCTTTCAGATGT-3') (forward) and PvDR (5'-
AACGCATTGCAGTTCTCCGA-3') (reverse) were used for nested PCR 
with the following cycling parameters: a 10 minute initial denaturation step 
at 94°C followed by 35 cycles with a 30 second denaturation step at 94°C, 
a 30 second annealing step at 54°C, a 1 minute extension step at 72°C. 
and a final 10 minute extension step at 72°C. Primers PvDA (covering- 75 
to - 55 bp upstream to the pvdhfr-ts start codon), PvDB, PvDF, and PvDR 
were designed from the known pvdhfr-ts sequence of pyrimethamine -
sensitive P. vivax isolate ARIZ Pakistan (X98123). 
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An individual band of each PCR product was excised from the agarose 
gel and purified by using AccuPrep ® gel purification kit (Bioneer 
corporation Korea) following manufacturer's instructions which are as 
follows: 
Gel purification: 
1. The DNA band of agarose gel was excised as small as possible and the 
gel slice weighed in a clean 1.5 ml micro centrifuge tube. The size of 
gel slice should be less than 400 mg. 
2. 5 volumes of GB buffer were added to the 1 volume of the gel slice for 
the DNA fragment of 100 bp-2 kb. (For example, if the weight of the gel 
is 150 mg that contain 1 kb fragment, add 750 pi of GB buffer). 
3. Incubation was done at 60 °C for 10 minute. After incubation, it was 
ensured that there were no unwanted particles of agarose gel. 
4. 1 gel slice volume of absolute isopropanoi was added and mixed gently. 
5. Binding column tube was placed in a 2 ml tube. 
6. The sample was applied to the binding column tube. 
7. Centrifugation was done for 30-60 second to make the sample pass 
through the binding column tube. 
8. Flow through was discarded and the binding column tube was placed in 
the same tube. 
9. 500 pi of GB buffer was added to the binding column and centrifuged 
for 1 minute. 
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10. 500 J^1 of WB buffer was added to the binding column tube and again 
centrifuged for 30-60 second for washing. 
11. Flow through was discarded and the binding column tube was 
placed In the same tube again. 
12. Washing procedure was repeated using 500 \i\ of WB buffer. 
13. Binding column tube was centrifuged for an additional 2 minutes for 
drying so that WB buffer could be removed completely 
14. Binding column tube was then placed in a clean 1.5 ml tube. 
15. 30 pi of EL buffer was added to the center of the binding column 
filter as possible, and the column allowed to stand for 1 minute. 
16. Finally the column was centrifuged for 1 minute to elute. 
Nucleotide sequencing: 
The nucleotide sequences were translated into amino acids using 
the Edit sequence programme (Lasergene, version 5.1 July, 1999; 
DNASTAR Inc., Madison, Wl). Amino acid sequences were aligned using 
the Gene Doc Multiple Sequence Alignment Editor and Shading Utility 
(Version 2.6.002). 
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RESULTS 
During 2003 and 2004 blood films were prepared from febrile 
patients for the diagnosis of vivax and falciparum malaria. From the 
confirmed cases 100-200|JI heparinised blood was collected for the 
extraction of DNA and nucleotide sequencing. Nucleotide sequences of the 
entire DHFR gene from 39 samples of P. falciparum and 38 samples of P. 
vivax were successfully studied and genotypes showing mutations were 
worked out. 
Mutation analysis of PFDHFR gene: 
Nucleotide sequencing results of the PFDHFR gene from 39 isolates 
of P. falciparum showing five genotypes, revealed mutations at different 
codons. (Table XII). P. falciparum isolates showed mutation at codon 108 
(S108N) in maximum number of cases followed by codon 59 (C59R). 
Double mutation in PFDHFR was very common (64.09%) as compared to 
single mutation which was recorded in (33.33%) isolates in the present 
study. Only one case (2.56%) out of 39 showed wild type of gene (Graph 
13). This shows different level of drug resistance and malaria transmission 
patterns in different pockets of Aligarh which is plain main land where P. 
vivax is prevalent and is the dominant species. None of the cases showed 
triple or quadruple mutations. 
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Mutation analysis of PVDHFR gene: 
Nucleotide sequencing results of the PVDHFR-ts gene from 38 
isolates of P. vivax showing four genotypes, revealed mutations at different 
codons (Table XIII). Twenty two (57.98% n = 38) isolates contained the 
wild type amino acid which were at their respective positions. Among the 
remaining isolates, 13 (34.21%), showed the frequency of double,DHFR 
mutations which was highest. While three isolates constituting (7.89%) 
showed only single DHFR mutations (Graph 15). Besides the non 
synonymous mutations, there was a synonymous mutation at codon 69 
(TAT -> TAG) coding for tyrosine. TAT at codon 69 was associated with all 
the different PVDHFR genotypes and was present in majority of the 
isolates. On the contrary isolates containing TAG at this codon were 
associated with the wild type PVDHFR genotype (Table XIV). 
There were variable numbers of GGDN repeats at amino acid 
position number 88 of PVDHFR among P. vivax isolates. The majority of 
these were found to contain three GGDN repeats while isolates with wild 
type PVDHFR genotype had a variable number GGDN repeats. The 
majority of the isolates with mutated genotype contained only three GGDN 
repeats (Table XIV). 
Distribution of PFDHFR alleles: 
Among 39 P. falciparum isolates from Aligarh collected during 2003-
2004, majority contained double mutations 25 (64.09% n=39), the 
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genotypes for which were A16N51R59N108I164, Ai6i5iC59Nio8li64 and 
Ai6N5iC59Nio8Li64- While genotype showing single mutation was 
Ai6N5iC59Nio8h69 constituteol 13 isolates (33.33% n=39). Only one wild 
case was detected out of 39 samples (2.56% n= 39) having genotype 
A16N51C59S108I164. (Table XII and Graph 14). 
Distribution of PVDHFR alleles: 
Among 38 isolates of P. wVax collected from Aligarh during 2003-
2004, majorities of them contained wild type amino acids at the 5 codons 
of PVDHFR with genotype F57S58T61S93S117. Genotypes showing single 
mutation in Aligarh were F57S58T6iS93Nii7and F57S58T61H93S117 constituted 
3 cases (7.89% n=38). While genotype showing double mutations was 
F57R58T61S93N117 in 13 isolates constituting (34.21% n= 38). (Table XIII and 
Graph 16). 
Relationship between PFDHFR and PVDHFR mutations: 
P. falciparum and P. vivax infections occur in study area of Aligarh 
where analysis of gene mutations in PVDHFR and PFDHFR was carried 
out in 38 and 39 sample, respectively. A comparison was also made to see 
the trend of mutations in aforesaid species in the same experimental area 
having co-infection. As shown in Graph 17. There was a specific trend of 
DHFR mutations across the P. falciparum and P. vivax groups. 
Nevertheless, the frequency of wild type PFDHFR genotype was 
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significantly higher than that of PFDHFR genotype which was in a very low 
percentage. Double DHFR mutations were higher than single DHFR 
mutations In both the species. 
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Type 
1 
II 
III 
IV 
V 
Genotype 
A16N51C59S108I164 
Ai6N5iC59N[i08ll64 
A16N51R59N1 08ll64 
A16I51C59N1O8I164 
AieNsiCsgN i^os ki64 
No. of 
mutations 
0 
1 
2 
2 
2 
No (%) of isolates 
of Aligarh (n = 39) 
1(2.56) 
13(33.33) 
22(56.41) 
1(2.56) 
2(5.12) 
Mutated amino acids are shown in underline and boldface 
Table XII. DHFR genotypes among P. falciparum isolates of Aligarh 
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Genotype 
F57S58T61S93S117 
FsrSssTeiSgaNliiy 
FsrSssTeiilgaSii? 
F57E58T61S93N117 
No. of mutations 
0 
1 
1 
2 
No (%) of isolates of 
Aligarh (n = 38) 
22(57.89) 
2(5.26) 
1(2.63) 
13(34.21) 
Mutated amino acids are shown in underline and boldfece type 
Table XIII. DHFR genotypes among P. vivax isolates of Aligarh 
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Allele 
A1 
A2 
A3 
A4 
A7 
A8 
A9 
Mutate 
Genotype 
F57S58T61S93S117 
F57S58T61S93S117 
F57S58T618938117 
F57858T61S93S117 
F57S58T61893N117 
F57858T61S93N117 
F57858T6l|H93Sii7 
d amino acids are sho\ 
Synonymous 
Mutation at 
codon 69 
TAT 
TAG 
TAT 
TAT 
TAT 
TAG 
TAT 
vn in underline and bo 
Type of GGDN 
repeat" 
1 
1 
2 
3 
1 
1 
5 
dfece type 
Types of GGDN repeats are defines as follows: type1, GGDNTSGGDNTHGGDN; type 2, 
GGDNTHGGDN; type 3, GGDNTSGGDN; type 4, GGDNTSGGDNTHGGDNTHGGDN; type 5, 
GGDNTHGGDNTHGGDNTHGGDN 
Table XIV. Allelic variation in the pvdhfr gene among P. vivax isolates 
of Aligarh 
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Graph 13. Distribution of R falciparum DHFR 
mutations in the isolates of Aligarh 
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Graph 14. Distribution of P. falciparum DI-IFR 
genotypes in the isolates of Aligarh 
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Graph 15. Mutation patterns of DHFR in 
P. vivax isolates of Aligarh 
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Graph 16. Distribution of P. vh/ax DHFR 
genotypes In the isolates of Aligarh 
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Graph 17. Mutation patterns of P. falciparum and P. vivax 
DHFR 
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DISCUSSION 
Antifolate drugs are commonly used for the treatment of falciparum 
malaria. According to the National Drug policy of India, chloroquine 
resistant uncomplicated falciparum malaria cases should be treated with 
sulfadoxine-pyrimethamine. In those regions of India where chloroquine 
resistance has reached a very high level, sulfadoxine-pyrimethamine is the 
first line of antimalarial drug, except for a few primary health centers, 
where artesunate based combined therapy has recently been introduced 
as an alternative treatment. If P. falciparum and P. vivax species co-exist 
in the region, both of them are at risk of being exposed to the antifolate 
drugs, as they have common target (de Pecoulas et al. 1998 & Gregson 
and Plowe, 2005). We observed that the antifolate drug pyrimethamine 
was also affecting the P. vivax parasite, as PVDHFR mutations were 
observed among isolates of Aligarh (U.P). This may be due to the fact that 
both of these species co-exist together in this area, and chloroquine 
resistant falciparum malaria is treated with sulfadoxine-pyrimethamine 
(Sharma, 1999). Exposure of P. vivax to sulfadoxine-pyrimethamine can 
occur in this area for several reasons. First, there could be a situation 
where the clinicians prescribe the antimalarial drugs based on clinical 
grounds but lacks the opportunity of immediate diagnosis, and the 
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inaccurate diagnosis of the parasitic species also leads a similar situation. 
Second, economic issues can also lead to the treatment of P. wVax 
malaria with sulfadoxine-pyrimethamine because it is cost effective, easily 
available and simple to administer due to its single dose treatment 
regimen. Third, mixed P. falciparum and P. wVax infections may also be a 
reason for such a situation. Mixed infections are quite common in India 
despite the fact that there is separate transmission peak for each species 
(Singh et al. 2000). This may be due to the fact that there is a window 
period that overlaps between the peaks and provides a congenial 
environmental condition for the transmission of both the species. 
We have recorded wild type of DHFR in P. vivax from 22 (57.89%) 
cases out of 38 showing genotype F57S58T61S93N117 from Aligarh (U.P.). 
Alam et al. 2007 revealed wild PVDHFR showing lot of variations from 
different regions of India. They observed highest wild PVDHFR (91.66%) in 
M.P. This figure is much higher than that of our experimental area, Aligarh. 
They have also recorded variable wild PVDHFR percentage of 36.66, 
30.00, 29.16, 23.08 and 21.05 from Andman & Nicobar, Tamil Nadu, 
Assam, Orissa and Goa. These figures were much less than that of Aligarh 
(U.P). Similarly lots of variations were recorded by the same workers 
(Alam et al. 2007) in pvdhfr gene which got mutated in aforesaid regions. 
They reported double mutations with genotype F57R58T61S93N117 in variable 
percentage (i.e. 78.94, Goa; 76.93, Orissa; 70.00, Tamil Nadu; 8.33, 
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Madhya Pradesh). However, double mutation of PVDHFR in Assam and 
Andman & Nicobar Island was about 54.16% and 23.33%, respectively, 
involving two genotype viz. F57R58T61S93N117 and L57R58T61S93S117. While 
quadruple mutation was also recorded in 16.66% isolates of Assam and 
40.00% isolates of Andman & Nicobar having genotype L57R58M61S93T117. 
From our area of Aligarh 13 cases out of 38 (34.21%) showed double 
mutation with genotype F57R58T61S93N117 which is common to the 
genotypes of above mentioned region of India and one additional 
genotype of L57R58T61S93S117 was also recorded from Assam and Andman 
& Nicobar Island. These two places also witness quadruple mutation 
having genotype L57R58M61 
S93T117 which was not recorded from other 
region as well as our area of study. From our study area we have recorded 
three cases (7.89% n=38) showing single mutation in genotypes 
F57R58T61S93N117 and F57S58T61H93S117. No such mutations were recorded 
from other places like M.P, Goa, Orissa, Assam, Tamil Nadu and Andman 
& Nicobar. This result from different regions of India clearly indicates 
regional variation in the PVDHFR mutation rate. The probable explanation 
for variation is this that in above mentioned regions where P. falcipamm is 
' a dominant species and sulfadoxine-pyrimethamine is more frequently 
used to treat P. falciparum malaria also exerts pressure on P. vivax, as it 
co-exists with P. falciparum, and also when sulfadoxine-pyrimethamine 
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was given as presumptive treatment without prior microscopic examination 
for confirmation of specific diagnosis. 
Andman & Nicobar, Tamil Nadu, Goa, Orissa and Assam witnessed 
much higher rate of double mutations. Assam and Andman & Nicobar had 
two genotypes instead of one recorded from other region. A different 
genotype for quadruple mutation was observed from these two areas only. 
It may be because of the simple reason that in these areas sulfadoxine-
pyrimethamine pressure is very high as this drug is frequently used to treat 
falciparum malaria and since P. v/Vax co exist with P. falciparum, it is also 
under sulfadoxine-pyrimethamine pressure and mutated like P. falciparum, 
as both these parasites have common drug targets. In Madhya Pradesh 
double mutation is lowest (8.33%) indicating that here chloroquine is still 
used as curative drug for the treatment of P. falciparum malaria. 
- Sulfadoxine-pyrimethamine is only used in complicated falciparum cases. 
Moreover P. vivax is found in less numbers which is probably the reason 
for less percentage of mutation in Madhya Pradesh. In our experimental 
area Aligarh, we got 34.21% P. vivax cases which showed double mutation 
and is less as compared to most of the region studied by Alam ef a/. 2007. 
Madhya Pradesh which showed lowest double mutation (8.33%) is less 
than that of our study area Aligarh. In our study area sulfadoxine-
pyrimethamine pressure exists and P. falciparum coexists with P. wVax 
and is now treated by sulfadoxine-pyrimethamine combination therapy in 
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good number of cases as a result of which double mutation has taken 
place which is less in P. vivax but comparable to that of P. falciparum. In 
our study area single mutation is also observed in 7.89% cases while from 
other parts of India such mutations were not recorded. We do not find any 
satisfactory explanation for this. 
Similar regional variation in the PVDHFR mutations from Indian 
subcontinent was also described previously by Kaur et al. 2006. Rates of 
PVDHFR mutations reported from Chennai and Goa were higher than that 
of our data. The same group simultaneously reported still higher rate of 
PVDHFR mutations from Chennai (Valecha et al. 2006) using a different 
methodology, i.e. PCR restriction fragment length polymorphism, which 
could not be as accurate as sequencing, moreover these areas have much 
more sulfadoxine-pyrimethamine pressure than what exists in our area. 
Imwong et al. 2001 also analysed a few Indian isolates (n =16) and found 
double PVDHFR mutation in 19% of them which is less than what we 
observed in Aligarh. Kaur et al.2006 reported PVDHFR mutation rate of 
29.75% from 121 isolates which was very close to our findings (34.20%). 
This similarity is probably because of the reason that P. vivax isolates in 
our study and those studied by Kaur et al. 2006 were obtained from 
Northern India, where wild type PVDHFR predominates. However, we did 
not find any isolate with PVDHFR mutation at codon 37, 109, 131, 159, 
171 and 188 which were considered novel by Kaur et al. 2006. This 
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discrepancy may be due to different approaches used for sequencing as 
Kaur et al. cloned the PCR products and then sequenced them, whereas 
we employed direct sequencing of the PCR products. 
It seems that there is selective pressure (positive natural selection) 
on the PVDHFR gene leading to the increased frequency of some of the 
alleles (Table). However, selective sweep of any particular allele can not 
be suggested at this time point; since the flanking natural markers for each 
of the mutant PFDHFR alleles are not yet fixed in the population. This is 
because we have observed an enormous heterogeneity in these markers 
for each PVDHFR mutant allele among the isolates (Alam et al. 2007). 
Interestingly, the PVDHFR mutation pattern was similar to that of PFDHFR 
' mutation pattern among the isolates. There was a specific trend in DHFR 
mutation across the species. Isolates from our study area and other 
regions followed the similar PVDHFR and PFDHFR mutation pattern. 
Similar DHFR mutation trends across the species indicate that sulfadoxine-
pyrimethamine treatment of P. falciparum patients also affected the 
P. vivax parasite population. 
Although we have observed similar DHFR mutation pattern for both 
the species, there was a significant difference in the rate of DHFR 
mutations between P. vivax and P. falciparum. The overall DHFR mutation 
rate for P. vivax was significantly lower than that of P. falciparum. 
Considering the fact that sulfadoxine-pyrimethamine is used for 
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p. falciparum malaria treatment and not for P. vivax. The latter parasite 
expectedly showed the lower rate of DHFR mutations among all the 
regions of the country including our experimental area. However, the 
frequency of PVDHFR mutation was higher in the P. falciparum dominated 
area and lower in P. vivax dominated area except Goa and Tamil Nadu 
(Alam et al. 2007). Sulfadoxine-pyrimethamine resistance also varies in 
our experimental area and other regions, and it is higher in the 
P. falciparum dominated areas due to its expectedly higher usage as in • 
Andman & Nicobar Island and Assam (Ahmad et al. 2006a). Among the 
main land isolates the quadruple PVDHFR mutations were observed only 
in Assam, where sulfadoxine-pyrimethamine pressure was higher since it 
is the first line drug to treat falciparum malaria in this area (Sharma, 1999). 
Therefore, it seems that the rate of PVDHFR mutations increased in 
P. falciparum dominated areas which had higher usage of sulfadoxine-
pyrimethamine, and vice versa. Surprisingly, so far, no P. falciparum 
isolate from Assam had been found to contain the quadruple PFDHFR 
mutations as seen in Andman & Nicobar (Ahmad etal. 2006a). 
In our study area we observed double mutations in PFDHFR against 
sulfadoxine-pyrimethamine in 64.09% of P. falciparum isolates, while 
Biswas et al. 2000 recorded 80% mutant type alleles in codon 108 and 
31% in codon 59 of DHFR from Indian isolates. Ahmad et al. 2006a 
-reported higher rates of 70.00%, 76.92% and 78.94% in Tamil Nadu, 
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Orissa and Goa and lower rates of 23.33% and 50% in Andman & Nicobar 
and Assam. Nazila et al. (2000) detected PFDHFR mutations in 26% of the 
isolates of Kenya which is less than what we observed in Aligarh. In our 
study area we do not find any triple mutation. Nazila et al. 2000 got 44% of 
the cases with triple mutation while Ahmad et al. (2006a) reported triple 
mutation in only 12.82% isolates of Assam and Andman & Nicobar. We did 
not get any quadruple mutation in Aligarh while Ahmad et al. (2006) 
reported quadruple mutation in 28.20% isolates from Andman & Nicobar. 
In our area and Kenya none of the isolates showed quadruple mutations. 
Indeed we have not detected any quadruple PFDHFR mutations among 
the mainland isolates so far (Ahmad et al. 2006a).These results indicates 
that the P. falciparum strain from Andman & Nicobar reported by Ahmad et 
al. (2006a) are probably different from those of South East Asia strain or 
quadruple mutation in PVDHFR arise faster than those in PFDHFR. This 
requires further investigations. It seems from our results that antifolates 
used for P. falciparum are also affecting P. vivax mutations. This warrants 
careful usage of antifolates in order to check the development of cross 
species resistance. 
A probable explanation of resistance against pyrimethamine-
sulfadoxine may be that when chloroquine resistant parasites have spread 
through out the world specially Africa and South East Asia, pyrimethamine-
sulfadoxine has increasingly become the drug combination of choice for 
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the treatment of uncomplicated malaria. Pyrimethamine is inhibitor of 
dihydrofolate reductase (DHFR), which is one of the components of 
bifunctional proteins, the other component being thymidylate synthetase 
(Bzik et al. 1987). Sulfadoxine is thought to act against dihydropteroate 
synthetase (DHPS), a bifunctional protein that combines with 
hydroxymethypterin pyrophosphokinase (Brooks et al. 1994; Triglia and 
Cowman, 1994). 
The inhibiting activity of each drug is greatly augmented when they 
are used in combination, but the mechanism of this synergism is not yet 
understood (Nazila et al. 2000). It is estimated that its useful therapeutic 
life (UTL) is only 5 years. Several theories have been advanced to explain 
. the short UTL of pyrimethamine-sulfadoxine. Uncontrolled drug use and 
inadequate dosage are cited frequently (Winstanley et al. 1992), but the 
importance of the pharmacokinetic profile of the drug is rarely considered. 
Pyrimethamine-sulfadoxine have long elimination half-lives (81 and 116 
hours), respectively (Winstanley et al. 1992), which initially was thought to 
be an advantage because of the substantial prophylaxis conferred, but 
detailed follow-up has shown that, for 15-52 days after pyrimethamine-
sulfadoxine treatment, there is a strong selection pressure for 
pyrimethamine resistance.(Watkins and Mosobo, 1993). Nazila et al. 2000 
believe that selection pressure might be minimized if short acting antifolate 
drugs were used, despite the disadvantage of a longer dosage regimen 
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(Amukoye et al. 1997). They also suggested chlorcycloguanil (CCG) 
having half lives of 12-20 and Dapsone 22-30 hours, respectively (Watkins 
et al. 1987 and Edstein et al. 1990) as a possible alternative for 
pyrimethamine-sulfadoxine. 
Genetic analysis of P. falciparum isolates shows mutation from 
serine to asparagines at codon 108(8108 N) in the DHFR gene increases 
resistance to pyrimethamine and that subsequent mutation from 
asparagines to isoleucine at codon 51(N51i) from cystein to arginine at 
codon 59 (C59R), and from isoleucine to leucine at codon 164 (I164L) 
progressively enhance pyrimethamine resistance (Hyde 1990). It has 
become apparent that pyrimethamine-sulfadoxine because of their long 
half life promotes development of resistance and mutations in DHFR (Nzila 
et al. 2000). Other factor which might be complicating the resistance 
problem is probably the incorrect diagnosis and improper treatment by the 
technicians and clinicians of the diagnostic centers and hospitals 
particularly in the rural areas where antimalarial drugs especially 
pyrimethamine-sulfadoxine are loaded unnecessarily as presumptive 
treatment in febrile patients complaining for headache and body pain. 
Majority of such cases generally happens to be viral infections which are 
quite common and have somewhat similar symptoms. The underlying idea 
in such treatments might be to avoid risk of fatality which P. falciparum 
. may cause, if not treated in time. 
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With the foregoing discussion on findings obtained in present study 
and observations made by other workers it becomes very clear that there 
is an urgent need of training technicians of different clinics responsible for 
specific diagnosis of malaria parasite on good quality microscope; and 
strict regulation for the prescription of those antimalarials having different 
biochemical targets, having short half lives and are effective in resistant 
cases. If these precautions have not been undertaken drug resistance in 
P. falciparum and P. vivax will further increase against latest generation of 
antimalarials, if given as monotherpy. Therefore, it may be concluded with 
" the remarks that the drugs which are effective against the resistant cases 
must be used in combination therapy as advised by WHO, of course after 
careful observation and specific diagnosis of the malaria parasite. These 
measures can help in curtailing the existing problem of drug resistance and 
malaria control to some extent. 
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Summary 
SUMMARY 
The Thesis entitled "Vector screening, relapse and resistance 
patterns of malaria in Aligarh" comprises of 3 chapters. First chapter is 
regarding screening and incrimination of malaria vector. Second pertains 
to relapse and resistance patterns of Plasmodium vivax and Plasmodium 
t 
falciparum against chloroquine. While third chapter is about resistance in 
P. falciparum and P. vivax involving DHFR mutation against 
pyrimethamine-sulfadoxine combination which is generally used in 
resistant falciparum cases. 
For vector screening mosquitoes were collected from different 
localities of Aligarh, in the early moming and evening from cattle shed and 
. human dwellings. Mosquitoes were anaesthetized with ether and identified 
on the basis of morphological features with the help of standard regional , 
pictorial key of Wattal and Kaira (1961). For vector incrimination three 
suspected species viz. An. culicifacies, An. Stephens! and An. annularis, 
collected from human dwellings during high transmission season were 
dissected to look for the salivary gland and gut infection. Sprozoite positive 
slides were stained with Leishman's stain. For human blood index, blood 
smears were prepared from the gut of fully fed female anophelines on 
Whatman filter paper no.1 and analysed by counter current 
electrophoresis. 
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Survey for the screening of anopheline mosquito was carried out 
from December, 2000 to November, 2002 in Aligarh revealed the presence 
of seven species i.e. An. culicifacies, An. subpictus, An. annularis, An. 
Stephens!, An. vagus, An. barbirostris, and An. lindesayi. An. culicafacies 
was the predominant species (37.02%) in the area followed by An. 
subpictus (35.01%), An. annularis (16.07%), An. stephensi (8.78%) and 
An. vagus (2.68 %). Whereas rest of the anopheline species i.e. An. 
barbirostris (0.22%) and An. lindesayi (0.21%) were recorded less than 
one percent in Aligarh. 
Most of the anophelines were quite abundant during post monsoon 
season (i.e. from July to November). During these months moderate 
temperature (26-28°C) and optimum humidity (77-88%) prevailed which 
were ideal for breeding of mosquitoes and accounted for increase in 
mosquito density. An. culicifacies and An. stephensi showed liking for 
" human blood. Human blood index for the aforesaid species were 37.80% 
and 39.5%, respectively. An. culicifacies and An. stephensi were found 
positive for sporozoites. Sporozoite positivity rates recorded for An. 
culicifacies and An. stephensi vjere 0.41% and 0.26%, respectively. 
Thin and thick blood smears of the suspected malaria patients were 
prepared by finger prick and stained with J.S.B. and Giemsa stain, and 
examined microscopically for the positivity of malaria infection. For the 
study of relapse and resistance, patients were treated with standard dose 
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of chloroquine according to the National drug Policy of India and followed 
up carefully. Seasonal correlation of these infections was also studied. 
Relapse and resistance rates were determined in Plasmodium vivax and , 
Plasmodium falciparum infections during 2001, 2002 and 2003. Relapse 
rates were 15.2%, 19.1% and 17.1% while resistance rates were 9.6%, 
10.8% and 11.4%, respectively. Peak transmission of malaria with a slide 
positivity rate 61.76 to 50.14%, was recorded during September and 
October which happens to be the peak transmission months. Lowest 
transmission was recorded during March and April when slide falciparum 
rate was minimum (5.12%-9.25%). 88 patients who were administered 
with 1500 mg chloroquine and 75 mg primaquine in divided doses also 
showed relapse rate of 4.5%. Short term relapses were more then the long 
term relapses in the ratio of about 4:1.Three chloroquine resistant cases of 
Plasmodium vivax were also recorded in the present study. Patients 
suffering from falciparum malaria showed resistance against chloroquine in 
9.6, 10.8 and 11.4% cases after getting 1500 mg chloroquine base in 
- divided doses (i.e. 600 mg on day 0, 300 mg after 8 hours followed by 300 
mg daily for 2 days). Level of resistance in these cases was of R I and Rll , 
type. 
For pyrimethamine resistance associated mutations in Plasmodium 
vivax and Plasmodium falciparum thick and thin blood smears of the 
patients were stained and screened by light microscopy. 100-200 pi of 
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heparinized blood was collected from malaria positive patients. Parasite 
DNA was extracted from the blood of P. wVax and P. falciparum patients 
using Accu Prep Genomic DNA extraction kit (Bioneer Corporation, 
Korea). The DNA was eluted in Tris-EDTA buffer (pH 8.0), and an aliquot 
was used for the PCR amplification A 1,014-bp fragment of P. vh/ax dhfr-
ts gene was amplified using primers PvDA (5'- ACCGCACCAGTTCCTAC-
3') (forward) andPvDB(5'- TGTTAAAGCTGAAGTACACGAG-3') (reverse) 
with different cycling parameters. The primary PCR product was diluted 10 
times and used as a DNA template for nested PCR to amplify the 784-bp 
region which covers the entire DHFR domain Primers PvDF (5'-
ATGGAGGACCTTTCAGATGT-3') (forward) and PvDR (5'-
- AACGCATTGCAGTTCTCCGA-3') (reverse) were used for nested PCR 
with the different cycling parameters. For nucleotide sequencing an 
individual band of each PCR product was purified using an Accu Prep gel 
purification kit (Bioneer corporation, Korea).The entire pvdhfr gene was 
sequenced using primers PvDM (5'- GTTAGCGTCTTGGAAAGCAC-3') 
and PvDR. For P. falciparum, DNA was extracted and subjected to PCR 
amplification of a 720-bp fragment of the pfdhfr gene by using primers 
AMP-1(5'-TTTATATTTTCTCCI I I I iA-3^) and AMP-2(5'-
CATTTTATTATTCGTTTTCT-3'). An aliquot of the primary amplificon was 
diluted and subjected to the seminested PCR using primers AMP1 and 
DHFRR2 (5" ACAGAAATAATTTGATACTCA-3'). The PCR products were 
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purified and subjected to nucleotide sequencing using an ABI big dye 
terminator ready reaction kit, version 3.1 and ABI prism 310 genetic 
analyzer (PE Applied Biosystems, California). The nucleotide sequences 
were translated into amino acids using the Edit sequence programme 
(Lasergene, version 5.1 July, 1999; DNASTAR Inc., Madison, Wl). Amino 
acid sequences were aligned using the Gene Doc Multiple Sequence 
Alignment Editor and Shading Utility (Version 2.6.002). 
Nucleotide sequencing result of DHFR domain of P. falciparum isolates 
showed double mutations in PFDHFR in 64.09% cases, while single 
mutation was observed in only 33.33% cases in Aligarh. The genotypes in 
P. falciparum having double mutation were A16N51R59N108I164, 
A16I51C59N108I164 and AieNsiCsgNioskiB .^ while those having single mutation 
were AisNsiCsgNioelieg- Wild type which constituted only 2.56% having 
genotype A16N51C59S108I164 
In case of P. vivax majority of isolates (57.98%) contained wild type 
of amino acids in DHFR. However, frequencies of double and single 
mutations in PVDHFR were 34.21% and 7.89%, respectively. Majority of 
the isolates with mutated genotype contained only three GGDN repeats, 
while wild type PVDHFR genotype had variable number of GGDN repeats. 
Among isolates of P. wVax wild type of amino acids at the 5 codons of 
PVDHFR were F57S58T61S93S117 Genotypes showing single mutation were 
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F57S58T61S93N117 and F57S58T61H93S117, while genotype showing double 
mutations was F57R58T61S93N117. 
In our experimental area pyrimethamine and sulfadoxine 
combination was used as alternative treatment for resistant P. falciparum 
and also in normal cases without confirmation of specific diagnosis. This 
tendency increased the drug pressure on both P. vivax and P. falciparum, 
as they co-exist. Both these parasites got affected as they have common 
drug target (DHFR). This led to the gene mutations in PFDHFR and 
PVDHFR. Although similar DHFR mutation patterns v^ere observed, there 
was a significant difference in the rate of DHFR between P. vivax and P. 
falciparum. The overall DHFR mutation rate for P. vivax was significantly 
lower than that of P. falciparum. Considering the fact that pyrimethamine-
sulfadoxine is used for P. falciparum malaria treatment and not for P. 
vivax. The latter parasite expectedly showed the lower rate of DHFR 
mutations. It is estimated that the useful therapeutic life (UTL) of 
pyrimethamine-sulfadoxine combination, showing enhanced inhibitory 
. antifolate activity is only 5 years. If its indiscriminate and uncontrolled use 
could not be checked it may result in further more mutations and drug 
resistance, as this drug combination is retained in the body of the patient 
for longer duration because of its longer half life. 
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Anopheles culicifacies a Predominant Vector of Malaria in 
Aligarh 
VVAJIHULLAH* AND M.A. SAIFI 
Parasilolof^y Scclion. Deparliiiail 0/ Zoolog\; 
Aligarh Muslim University. Aligarh - 2()20()2. UP., India 
Anopheles culicifacies was incriminated as malaria vector in Aligarh by finding sporozoites in 
salivary glands. Sporozoite positivity rate and human blood index recorded for An. culicifacies 
during peak transmission season (i.e. August to October, 2001) were 0.396% and 37.31%, 
respectively. ^ 
Keywords : Aligarh, Anopheles culicifacies. Malaria, Vector 
A nopheles culicifacies is primary vector ofmalaria 
I in India, Sri Lanka and Pakistan. It is considered 
10 be ihc chief rural and pcriurban vector ofmalaria in 
India (Subbarao ct a!., 1988). Involvement of 
An.culicifacies was observed in malaria transmission 
in hilly, plain and costal areas and even in urban areas 
in Orissa. (Nagpal and Sharma, 19X6). Since no 
dcnnitc information was available regarding the status 
of vector in Aligarh the present study was undertaken 
to determine the prevalence of known vector species 
and their possible role in transmission ofmalaria in the 
university campus and in its periphery. 
For vector incrimination anopheline mosquitoes were 
collected from human dwellings of different localities 
in the university campus and its periphery with the help 
of suction lube in the morning and in the days time 
during peak transmission sca.son (i.e. August to 
October, 2001). Mosquitoes were anaesthetized with 
.her and identified with the help of regional pictorial 
keys of Wattal and Kalra (1961). Identified 
mosquitoes were dissected to look for salivary gland 
infection. Sporozoite positive slides were stained with 
Leishman's stain as described by Choudhary and 
Ghosh (1982). Blood sinears were prepared from the 
gut of mosquitoes on Whatman filter paper No. I and 
analysed by Ouchterlony gel diffusion technique 
(1949) for the determination of human blood index 
(HBI). 
The results are summarised in Table-1 and 2. Three 
anopheline species, i.e. An. culicifacies. An. annularis 
and An. slephensi were identified. The mosquitoes 
* Corresponding Author 
were dissected for salivary glands and sporozoites 
were detected. Of these only An.culicifacies which 
was a dominant species was found positive for 
sporozoites (Table-1). Blood meal analysis showed 
HBI 37.31% for An.culicifacies (Tablc-2) indicating 
its moderate endophagic and cndophilic nature and 
slightly higher preference for huiuan blood as 
compared to bovine (Tablc-2). During present study 
sporozoite positivity rate was 0.396% and HBI 
37.31%. Sporozoite positivity rate was low probably 
because mosquitoes were collected randomly from 
different localities ofthe university campus. Low IIBI 
of37.31 % further minimised the chance of infect iviiy. 
Sporozoite positivity rate of 0.396% is a low count for 
malaria transmission but is not very low for a place like 
Aligarh which is not a high transmission region and 
moreover vector species (i.e. An. culicifacies). though 
found in good numbers only 37.31% of them showed 
positivity for human blood and a fair population of it 
was found to be cxophagie and cxophilic in nature and 
feeding on cattle as earlier reported by Kalra (1978) 
and Nagpal and Sharma (1985) who had reported 
cxophilic and cxophagie population of An. culicifacies 
from Tamil Nadu and Orissa. Our findings of 
incriminating An. culicifacies as probable vector in 
the university campus of Aligarh, showing posiivity 
rate of 0.396% is in corroboration with the findings of 
Ansari et al. (1986) who reported positivity rate of 
0.490% for An. culicifacies from Meerut. However, 
higher sporozoite positivity rate of 0.823%, 1.005% 
and 2.89% were recorded by Ansari et al. (1984), 
Annual rcport-MRC (1988) and Prasad and Sharma 
(1990) from the villages of Barcilly and Shahjahanpur 
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of Uttar Pradesh, respectively. Nagpal and Sharma 
(1986) reported positivity of 1.33% for An.cuiicifacies 
from Orissa. Incrimination oiAn.culicifacies by above 
workers in the villages of plains of Uttar Pradesh and 
plains, costal areas and even from urban areas of 
Orissa established its role in malaria transmission. 
The role of other vectors of malaria such as 
An.Stephens! and An.annularis could not be 
established in the present study as only a small number 
of these mosquitoes were dissected. It is however 
likely that these anophelines especially^/?, slephensi 
might be adding to ihc transmission along with An. 
culicifacies in hot and dry months of summer when 
ideal breeding sites for An. slephensi remain readily 
available. 
Table 1 : Results of disscciion of anophelines collected from 
human dwellings (August to October, 2001) 
Species 
.An. culicifacins 
.in. annularis 
.An. slephensi 
Nuiiibcrj 
collctitil 
1360 
MOO 
200 
Dissction positive Sporozoilc 
Gland Gland Positivity 
rate 
1010 4 0,396% 
502 0 
150 0 
Table I I : B lood meal analysis result of Anopheles culicifacies 
Tout numlxr of 
blood smear inilysis 
Numbtr pMinve Number positive Mixed 
for human blood for bovine blood 
«70 2S0 
37.31% 
200 
29,85% 
220 
32.8% 
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Quadraple mutations in the Plasmodium falciparum dihydrofolate reductase (PFDHFR) enzyme give rise to 
the highest level of pyrimethamine resistance leading to treatment failures. We describe here the presence of 
these quadruple mutations in a majority of P. fakiparum isolates from Car Nicobar (Andaman and Nicobar) 
Island, India. Isolates trom the mainland, however, continue to show a prevalence of double PFDHFR 
mutations and some with triple but none with quadruple mutations. In conclusion, the antifolate drug pressure 
is veiy high in the island, which should be a cause of concern for the malaria control program in the country. 
The antifolate drug pyrimethamine acts on the Plasmodium 
falciparum dihydrofolate reductase (PFDHFR) enzyme and 
therefore inhibits the folate biosynthesis pathway of the para-
site (7, 20). Certain point mutations in PFDHFR reduce its 
capacity to bind to this drug, resulting in the emergence of 
resistant parasite strains (4. 7, 11). Pyrimethamine resistance 
develops in a progressive manner, and treatment failure occurs 
if there are quadruple mutations (N51I plus C59R plus S108N 
plus I164L) in this parasite enzyme (11, 17, 19). Monitoring 
PFDHFR mutations have been proposed for evaluation of the 
efficacy of this drug (8,12, 14). Recently, we have described a 
temporal rise in PFDHFR mutations among Indian P. falcip-
arum isolates (1, 16). The mutation rate varied from state to 
state, and it was lower in Uttar Pradesh (UP) but higher in 
Assam (1). In the present study, we revisited these high-prev-
alence and low-prevalence drug resistance areas after a gap of 
2 years to monitor the drug pressure. We also included P. 
falciparum isolates from Car Nicobar Island (the Andaman 
and Nicobar group of Indian islands), where chloroquine re-
sistance was reported a long time ago (5, 6). 
Patients with fever attended the malaria clinics in UP (Ali-
garh), Assam (Kamrup), and Andaman and Nicobar (Car 
Nicobar). Their blood was screened for the presence of the 
malarial parasite by light microscopy. Malaria patients were 
given the prescribed antimalarial treatment according to the 
national drug policy (18). Briefly, patients from high-rislc areas 
(Car Nicobar) were treated with chloroquine (25 mg/kg of 
body weight) over a 3-day period, while patients from low-risk 
areas (Aligarh) received a single dose of chloroquine (10 
mg/kg of body weight). Patients from high-risk chloroquine 
resistance areas (Kamrup) were treated with a single dose of 
sulfadoxine (25 mg/kg of body weight) and pyrimethamine 
(1.25 mg/kg of body weight). All patients from high-risk areas 
also received a single dose of primaquine (0.75 mg/kg of body 
weight). About 20 to 50 jxl of heparinized blood was collected 
* Corresponding author. Mailing address: Department of Biotech-
nology, All India Institute of Medical Sciences, Ansari Nagar, New 
Delhi-110029. India. Phone: 91-11-26588145. Fax: 91-11-26589286. 
E-mail address: ydsharma_aiims@yahoo.com. 
from the P. falciparum-poskwe patients. Informed consent was 
obtained from the patients prior to the blood collection, fol-
lowing the institutional ethical guidelines. Parasite DNA was 
extracted and subjected to PCR amplification of a 720-bp frag-
ment of the pfdlifr gene as described before (1). An aliquot of 
the primary amplicon was diluted and subjected to seminested 
PCR using primers AMPl (13) and DHFRR2 (5'-ACAGAA 
ATAATTTGATACTCA-3'). Only 30 cycles were carried out 
for seminested PCR under the same conditions as for primary 
PCR. The PCR products were purified and subjected to nu-
cleotide sequencing using an ABl Big Dye Terminator Ready 
Reaction kit, version 3.1, and the ABI Prism 310 genetic ana-
lyzer (PE Applied Biosystems, California) as described before 
(2, 10). 
We have analyzed the nucleotide sequence of the pfdhfr 
gene from 117 Indian P. falciparum isolates. There was no 
isolate with the A16V and S108T mutations in PFDHFR; this 
is the target for cycloguanil, which is not being used in India. 
Further, there was no isolate with Bolivia repeats and the 
C50R mutation, as has been found elsewhere (12). The max-
imum number of isolates (96.58%) showed a mutation at 
codon 108 (S108N) followed by the C59R mutation (Fig. lA). 
The majority of the isolates were found to contain double 
PFDHFR mutations (Fig. IB). The double mutation C59R 
plus S108N was much more common (43.58%) than the N511 
plus S108N mutation (0.85%). Triple mutations C59R plus 
S108N plus 1164L or N51I plus C59R plus S108N were not very 
common, as they were found only in 5.12% and 7.69% of 
i.solates, respectively. Surprisingly, quadruple mutations N51I 
plus C59R plus S108N plus 1164L were found in more isolates 
(28.20%) than the triple mutations (12.82%) (Fig. IB). The 
regional distribution of the total number of PFDHFR muta-
tions showed a wide variation (Fig. 2A). Quadruple mutations 
were predominantly present only in Andaman and Nicobar 
isolates, while double mutations were common in UP and Assam. 
Triple mutations were present in Assam and in Andaman and 
Nicobar but not in UP. Conversely, single mutation was specific to 
UP. There were a total of six different combinations of pfditjr 
mutations (genotypes) among these isolates. Some of these ge-
notypes showed a regional bias (Fig. 2B). 
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We dcscnbc herep/d/j/r mutatior\s among P. falciparum iso-
lates from three different geographical regions of India. These 
regions are far apart from each other and show a different level 
of drug resistance and malana transmission patterns viz. a 
lower level of drug resistance and malana transmission in UP, 
where Plasmodium vtvax is prevalent, and a higher level of 
drug resistaiKx and intense perennial malana transmission in 
Assam and in Andaman and Nicobar, where P. falaparum is 
predominant (5. 6, 9, 15). The pfdhfr mutation pattern ob-
served here was also different for these regions, as it was lower 
m UP but higher in the other two areas (Fig. 2). Therefore, it 
seems that there is an association between the degree of ma-
lana transmission and the number of pfdhfr mutations. This is 
similar to the previous observations in which greater numbers 
of Pfcrt mutations, associated with a higher level of chloro-
quine resistance, were found among isolates from these high 
malana transmission areas (10) The PFDHFR mutations in 
UP and Assam isolates were similar to those reported earlier, 
except that at present there were more isolates with tnple 
C59R plus S108N plus I164L mutations in the latter state (1). 
Still, there was no isolate with quadruple mutations m Assam, 
although sulfadoxine-pynmethamine has been used there for 
more than two decades (9, 15). Surprisingly, quadruple muta-
tions were found only in Car Nicobar (Andaman and Nicobar) 
Island, and they were present m A majority of the isolates from 
this region (Fig. 2). In fact this is the first lime that we are 
reporting the quadruple PFDHFR mutations from India (Ta-
ble 1). Such quadruple mutations have been reported from the 
high drug resistance areas of Southeast Asia (3, 7). It is pos-
sible that the P. falaparum parasite from Andaman and Nico-
bar with these quadruple mutations has evolved independently 
here, as these islands are physically separated from the mam-
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FIG. 2. Regional distribution of P. falciparum dhfr mutations (A) and its genotypes (B) among Indian isolates. Mutated amino acids are 
underlined, n, number of P. falciparum isolates; A&N, Andaman and Nicobar. 
TABLE I. DHFR mutations in Indian i.solates of P./fl/c//7oram 
Type Genolype' No. of Geographiciil localiun uf isolates 
1 
II 
III 
IV 
V 
VI 
VII 
VIII 
AjriNsiCwNi,^!,,^ 
A|6N5iR5yN„ml,^ 
A|(Xsl^ *^y'^ nw'l(vl 
AiftNjiC^yNuK^LlW 
Au.N5iB «^iyM»)aLiM 
AKd^l^^V^KwiaU*-! 
0 
1 
2 
2 
2 
3 
3 
4 
Delhi, Uttar Pradesh, Assam, Orissa 
Delhi, Uttar Pradesh, Orissa, 
Asjam, Goa 
Delhi. Uttar Prade.sh, Ori.«a. 
Assam, Goa, Andaman and 
Nicobar 
Uttar Pradesh, Delhi, Assam. Goa 
Uttar Pradesh. Assam 
Assam, Andaman and Nicobar 
Orissa, Assam, Andaman and 
Nicobar 
Andaman and Nicobar 
" Cknotype A,ftIj,R5gN,ngL|M is from the present study, while other geno-
types are from a previous report (1). Mutated amino acids are underlined. 
land. Para.sites with these quadruple PFDHFR mutation.s show 
the highest level of antifolate resistance (11, 17, 19). This 
indicates that the drug pressure in this Indian island is much 
higher than on the mainland. For some reason, this has gone 
unnoticed by the national malaria control program. Unfortu-
nately, the national drug policy for this island has remained the 
same despite chloroquine resistance having been reported since 
1981 (5, 6). This warrants a systematic study on in vivo drug 
resistance followed by a change in the drug policy for this island. 
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The antifolate drugs sulfadoxine and pyrimethamine are commonly used to trtat Plasmodium falciparum malaria. 
However, they can also affect the Plasmodium vivax parasite if it coexists with P.falcipanun, as both species have 
common drug targets. Resistance to the antifolate drugs arises due to point mutations in the target enzymes of the 
respective parasite. To assess the cross-species impact of antifolate drug treatment, we describe here the dihydro-
folate reductase (DHFR) mutations among field isolates of P. vivax and P. falciparum. The overall DHFR mutation 
rate for P. vivax was lower than that tor P. falciparum. However, both species of Plasmodium followed similar trends 
of DHFR mutations. Similar to P.fakipantm, the DHFR mutation rate of P. vivax also varied from region to region. 
It was lower in P. viVor-dominant regions but higher in the P. /afciparum-dominated areas and highest where 
antifolates are used as the first line of antimalarial treatment In conclusion, the antifolate treatment of falciparum 
malaria is proportionately affecting the DHFR mutations of P. vivax, suggesting that the drug should be used with 
caution to minimize the development of cross-species resistance in the field. 
Sulfadoxine and pyrimethamine (SP), commonly used for Plas-
modium falciparum malaria treatment, interfere with the enzymes 
involved in the folate biosynthesis pathway of the parasite (8). 
Point mutations in Plasmodium falciparum dihydrofolate reduc-
tase (PFDHFR) are known to give rise to pyrimethamine resis-
tance. The first mutation occurs at the S108N codon, followed by 
C59R, N51I, and I164L mutations (8). One could observe single, 
double, triple, or quadruple PFDHFR mutations depending on 
the level of drug resistance. P. falciparum isolates with increased 
numbers of PFDHFR mutations were found to show a higher 
degree of pyrimethamine resistance (8). Indeed, the falciparum 
malaria patients containing quadruple PFDHFR mutations 
showed a treatment failure against this drug (8, 23). 
This antifolate drug also affects the Plasmodium vivax para-
site since both contain the same target enzyme (7). Py-
rimethamine resistance in P. vivax is associated with two key 
DHFR mutations, S58R and SH7N, which are equivalent to 
the C59R and S108N mutations of the PFDHFR (6). In addi-
tion, other mutations (I13L, P33L, F57L/I, T61M, S117T, 
1172V, and IITSL) in P vivax DHFR (PVDHFR) have al.so 
been reported (4-7, 9-12, 14, 16, 18, 22). Similar PVDHFR 
mutations at these codons except for 113L, P33L, 1172V, and 
1173L have al.so been reported in Indiaby various workers (11, 
14. 22). 
The in vitro and in vivo data on PVDHFR mutations have 
' Corresponding author. Mailing address: Department of Biotech-
nology, All India Institute of Medical Sciences, Ansari Nagar, New 
Delhi U0029, India. Phone: 91-11-26588145. Fax: 91-11-26589286. 
E-mail: ydsharma_aiims@yahoo.com. 
' Published ahead of print on 28 December 2006. 
now clearly established the association between pyrimeir;-
amine resistance and these mutations (9-11, 15, 20, 21). For 
example, the wild-type PVDHFR enzyme expressed in Esci-ic-
ricliia coli showed a higher catalytic activity than the mutint 
type enzyme (15, 20). Similarly, wild-type and different mutant 
alleles of PVDHFR were expressed in Saccliaromyccs rere-.-i-
siac and tested for their susceptibilities to pyrimethamine < 4. 
10). The yeast cells harboring the mutant PVDHFR constructs 
showed their survival at a higher concentration of pyrimeth-
amine than those cells that were harboring the \vild-t\pe 
PVDHFR construct (9). The degree of pyrimethamine resis-
tance in F. vivax also increases with the sequential addition of 
each mutation in the dlifr gene, and extremely resistant para-
sites carry an SI17T mutation (9, 10, 12). Therefore, tr.c 
PVDHFR allele with quadruple mutations (F57L plus S5.>R 
plus T61M plus SI 17T) exhibited the highest level of pyrime:h-
aminc resistance in the Saccliaromyccs ccrevisiae system (^). 
The P. vivax malaria patients harboring this quadruple muta-
tion were also unable to clear the parasite with pyrimethamine 
(21). The DHFR mutations of both Plasmodium species ha->c 
now been used as markers to assess antifolate drug pressure in 
the field (1-3, 5, 8. 10, 11, 14, 16, 18, 21-23). 
Although DHFR mutations have been described separate ly 
for P. vivax and P. falciparum from various countries, there is 
no report showing DHFR mutations of both .species together 
from the same region at a given time point, which can as.scss 
the cross-species effect of the antifolate treatment. Therefo-c. 
to asses the cross-species effect of antifolate usage, we decided 
to investigate the DHFR mutations among P. vivax and P. 
falciparum isolates from different parts of India, including 
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those areas where we have recently reported the PFDHFR 
mutations (2). 
MATERIALS AND METHODS 
Parasite colltction. Patients with fever were attending malaria clinics at Car 
NicolMr Island (Andaman and Nicohar Islands [A&N]), Kamrup (Assam), Ali-
garh (Uttar Pradesh [UP]), Panjim (Goa), Panna (Madhya Pradesh [MP]), 
Cuttack (Orissa), and Chennai (Tamil Nadu [TN)) during 2003 and 2004 (Fig. 1). 
Thick and thin blood smears of these patients were screened by light microscopy 
after Giemsa staining. Patients were treated with antimalarial drugs according to 
the National Drug Policy as described previously (2). Rrielly. the vivax malaria 
palicnls from Aligarh, Panna. Panjim, and Chennai were treated with a single 
do.se ofchloroquine (HI nig per kg hody weight) followed by primaquine (0.2.S mg 
per kg body weight) per day for 5 days. However, the /'. vivM patients from 
Kamrup. Cuttack, and Car Nicobar were treated with a total dose of 1,500 mg 
chloroquine over a .1-day period (600 mg, (M mg, and 300 mg for the first, 
second, and third days, respectively) along with the same dose of primaquine 
over a 5-day period. The f. falciparum malaria cases from these areas except 
Kamrup were treated with similar doses of chloroquine but a single do,se of 
primaquine (0,75 mg per kg body weight). The P. falcipumm malaria palicnls 
from Kamrup were treated with a single dose of .sulfadoxine (25 mg per kg body 
weight) and pyrimethamine (1.25 mg per kg btKjy weight). One hundred to 20(J 
M.I of heparinized blood was collected from the malaria parasite-positive patients. 
Informed consent was obtained from the patients prior to bKxid collection 
according to institutional ethical guidelines. Previously, we used the H. fakipa-
mm-infected blood samples from UP, Assam, and A&N for the PFDHFR mu-
tation studies (2). The remaining P. falciparum isolates from MP, Goa, and 
Orissa and the P. vivax-infected blood samples from all seven areas were used 
here for the DHFR mutation analysis. 
Extraction of parasite DNA and PCR amplification of the Jhfr gene. Parasite 
DNA was extracted from the blood of P. vivax and P. falciparum patients using 
an AccuPrep Genomic DNA extraction kit (Bioneer Corporation, Korea) ac-
cording to the manufacturer's instructions. The DNA was eluted in Tris-liDTA 
buafer (pH 8.0). and an aliquot was used for the PCR amplification. A 1,014-bp 
fragment of the /'. vivax dhfr-is gene was amplified using primers PvDA (.>'-AC 
CGCACCAGTrGATrCCTAC-.T) (forward) and PvDB (5'-TGITAAAGCTG 
AAC1TACACGAG-.3') (reverse) with the I'ollowing cycling parameters: a lO-min 
initial denaturation step at WC was followed by 35 cycle-s with a 30-s denaear-
ation step at 94°C. a 1-min annealing step at 58°C a l-min extensioo step at T^C, 
and a final lO-min extension step at 72°C. This primary PCR prodtict was diliaed 
10 times and u.<ed as a DNA template for nested PCR to amplify the 7!M-bp 
region, which covers the entire DHFR domain. Primers PvDF (5'-ATGGAGG 
ACCTrTCAGATGT-3) (forward) and PvDR (5'-AACGCATT<3CAGTTCTC 
CGA-3') (rex'erse) were used for nested PCR with the following c\cling param-
eters: a lO-min initial denaturation step at 94"C followed by 35 cydes with a 30-s 
denaturation step at 94*C, a 30-s annealing step at 54°C. a l-min extension siep 
at 72°C. and a final lO-min extension step at 72''C. Primers PvDA (covering - 7 5 
to -55 bp upstream to the pvditjr-ts start codon). P\'DB, PvDF, and P\DR '"ere 
designed from the known />i<//i/r-B wquencc of pyrimcthaminc-sensitK'e P. vnur 
isolate ARITakislan (X<)8I23). Amplification of the tlhfir gene from P. falcipa-
rum isolates was carried out under the same conditions as those described 
jwcviciusly \l\. 
Nudeolide sequencing. An individual band of each PCR product was exdsed 
from the agarose gel and purified using an AccuPrep gel purification kit (Bioneer 
Corporation, Korea) according to the manufacturer's instructioas. The ensire 
pvdhfr gene was sequenced using primers PvDM (5'-GTTAGCtj lUl IGGAA 
AGCAC-3') and PvDR. while primers for the pfiihfr gene sequencing were same 
as those described previously (2). Sequencing parameters and other downstneam 
protocols were the same as those described previously (13). The nucleotide 
sequences were translated into amino acids using the F.dit sequence program 
(LascTgcnc.N-ersion 5.\. July Vf*i. DNASTAR Inc.. MaJison, Wl). Amino »cid 
sequences were aligned using the GeneDoc Multiple Seijuencc Alignment Edi-
tor and Shading Utility (version 2.6.002). 
Statistical analysis. The chi-square test was applied to find significant differ-
ences between two groups. Furthermore, the chi-.square lest was also applied to 
assess the trends of DHFR mutations across the P. falciparum and P. m'ox 
groups. A P value of <0.05 was considered significant. 
RESULTS 
Mutation analysis of the pvdhfr gene. Wc have sequenced 
the entire DHFR domain of the fwdhfr-ts gene from 177 P. 
vivax cHnical isolates. Among these isolates, mutations were 
observed at F57L, S58R, T6IM, S9.1H, SII7N, and S1I7T 
I 
I 
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F57L S58R T61M S93H S117N S117T 
PVDHFR mutations 
Wild Single Double Triple Quadruple 
Type of PVDHFR mutations 
FSTSS FSTSN FSTHS LRTSS FRTSN LRMST 
PVDHFR genotypes 
FIG. 2. Mutation rates in the P. vivax DHFR enzyme. (A) Muta-
tion rate in individual PVDHFR codons. (B) Prevalence rate of the 
total number of mutations in PVDHFR. (C) Prevalence rates of the 
PVDHFR genotypes. The amino acid sequence (mutated amino acids 
are in boldface type) shown in the lower panel corresponds to 
PVDHFR codons 57, 58, 61, 93, and 117. 
codons (Fig. 2A). The mutation frequency at S58R and S117N 
was higher among the isolates. Seventy-six (42.94%; « = 177) 
isolates contained the wild-type amino acids at these positions. 
Among the remaining isolates, the frequency of double DHFR 
mutations was highest, while no isolate was found to contain 
triple DHFR mutations (Fig. 2B). The frequency of quadruple 
DHFR mutations was higher than the frequency of single and 
triple DHFR mutations. There were six different genotypes 
among these 177 isolates, where genotype F,7R,8T6,S,,N,,7 
was most prevalent, followed by L,7R5xMft,Sy3T||7 (mutated 
amino acids are in boldface type) (Fig. 2C). 
Besides the nonsynonymous mutations, there was a synony-
mous mutation at codon 69 (TAT-*TAC) coding for tyrosine. 
TAT at codon 69 was associated with all six different PVDHFR 
genotypes and was present in the majority of the i.solates 
(85.88%; n = 177). On the contrary. 24 of 25 isolates contain-
ing TAC at this codon were associated with the wild-type 
PVDHFR genotype. 
There were variable numbers of GGDN repeats at amino 
acid position 88 of PVDHFR among the P. vivax isolates. The 
majority of them (91.53%; n = 177) were found to contain 
three GGDN repeats, whereas the rest of them contained two 
(6.78%; n = 177) or four (1.69%; n = 177) repeats. While 
isolates with the wild-type PVDHFR genotype had a variable 
number of GGDN repeats, the majority of the isolates with 
mutated genotypes (98.02%; n = 101) contained only three 
GGDN repeats. 
Regional distribution of PVDHFR alleles. The majority of 
isolates from MP and UP contained the wild-type amino acids 
at the above-mentioned five codons of PVDHFR (Table 1). 
On the contrary, the majority of isolates from Goa, Orissa, and 
TN were found to contain the double DHFR mutation geno-
type Fs7R5sTh,Sv3N| ,7- This genotype was also predominant in 
Assam but not in A&N. The latter had a predominance of the 
quadruple DHFR mutation genotype L57R;sMft,S,j,T|,7. Geno-
types L57R58M6,893X117 and L,7R,gT(,,S93S||7 were present 
only among Assam and AN isolates, albeit with variable fre-
quencies, whereas F,7S.,HTft,S93N|,7 and F,7S,gTft,H,3S,i7 
were present only in UP (Table 1). 
Thirteen different PVDHFR alleles were observed among 
the 177 P. vivax isolates when variations at three different loci 
were considered, i.e., nonsynonymous mutations together with 
a synonymous mutation (TAT-»TAC) at codon 69 and GGDN 
repeats (Table 2). The most common alleles had a TAT codon 
at 69 and three GGDN repeats associated with the F57R5gT6, 
SyjN,,, (43.50%; n = 177) or FsTSsoTfiiS i^S,,, (22.60%; n = 
177) genotype. These two alleles (Al and Al 1) were present in 
a i 
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TABLE !. Geographical distributions of DHFR genotypes among Indian P. vivux isolates 
Genotype" 
FjTSjsTft 1 $91$, 17 
•^STSssTft 1 AQ^N 117 
F57S5sT(,lHi)jS,,7 
t-5 7**5sTft 1 Sg^S 117 
F s ? " .^ isTh 1 Sg^N 117 
LKi7R5)tM(,,SgxT| 17 
No. of 
mutation!. 
0 
1 
1 
2 
2 
4 
UP (n - i8) 
22 (57.89) 
2 (5.26) 
1 (2.63) 
13(34.21) 
MP (n = 24) 
22(91.66) 
2 (8.33) 
Goa (« - .18) 
8(21.05) 
30 (78.94) 
No. (%) of isolates 
Ori.ssa (n = li) 
3 (23.08) 
10(76.92) 
Assam (;i - 24) 
7(29.16) 
1 (4.16) 
12(50.(K)) 
4(16.66) 
IN (n - lU) 
3 (30.00) 
7 (70.00) 
A&N (« = 30) 
11 (36.66) 
3(10.00) 
4(13.33) 
12(40.00) 
Mutated amino acids are shown in boldface type. 
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TABLE Allelic variation in the p\dhfr gene among 
Indian P. viivtt isolates 
Allele 
Al 
M 
A3 
A4 
A5 
A6 
A7 
A8 
. \9 
AlO 
A l l 
A i : 
\\y 
V i . c^) 
ut isolHtes 
(« = 177) 
* f (22.60) 
I.-(12.99) 
- (.V95) 
* (2.26) 
t (036) 
I (0J6) 
I (056) 
I (0 J6) 
I (0.56) 
i (2.26) 
- (43.50) 
: (0 i5 ) 
Ifr (9.04) 
Genotxpe" 
^^TSVITMS^^SII? 
F5'7S<aTf,lSq3Si IT 
F*TS5nThiS»,iS| 17 
f^fTS^aT^iSq^iiT 
F57S«T6|S^lS 117 
F J T S M T J I S H ^ I I J 
F.^iSssTjiS^iNiij 
F5TS5>TtiS«N,i7 
FS7S«T|SI IUJS|17 
VrrRjaTftiS^jSin 
F^RjsT'uSq.iNi 17 
F<7R«Tfc|S<)3N, 17 
'-<7Rw^^»S^T) 17 
Synonynuius 
mulalion Ht 
codon 69 
TAT 
TAC 
TAT 
TAT 
TAT 
TAC 
TAT 
TAC 
T A T 
TAT 
TAT 
TAT 
T.AT 
Type of 
GGDN 
repeal* 
1 
1 
2 
3 
4 
4 
1 
1 
5 
I 
1 
3 
1 
Region(s) 
Ail regions studied 
Goa, UP, TN, MP, 
A&N. and 
Assam 
UP. TN. MP, 
Oris.<a, and 
A&N 
UP. Orissa, and 
MP 
A * N 
A & N 
UP 
UP 
UP 
AiScN and Assam 
All regions studied 
A&N 
A&N and Assam 
" MutJisd amino acids are shown in bold face. 
" Tvpes of GGDN repeats are defined as follows: tvpe I, GGDNTSGGDNT 
HGGDN. tvpe 2. CK3DNTHGGDN; type 3. GGDNTSGGDN; type 4, GGDN 
TSGGDNTHGGDNTHGGDN; type 5. GGDNTHGGDNTHGGDNTHO 
GDN. 
TABLE 3. Geographical distributions of PFDHFR genotypes 
among Indian I', falciparum isolates" 
Genotype'" No. of 
mutations 
No. (%) of isolates 
MP 
(n = 24) 
Goa Orissa 
(n = 22) (n = 27) 
'^(hNMCwSionI iM 
'^(ftNjiCsiiNKigli^, 
A|hN5|R59Nin(,IiM 
A|i,N5|RviNionL.tft4 
1(4,16) 
6 (25.00) 
17(70.83) 
4(18.81) 
18(81.81) 
4(14.81) 
22(81.48) 
I (3.70) 
" The PFDHFR mutations among/*, falciparum isolates from UP, Assam, and 
A&N have been described in our previous studies (2). The PFDHFR mutation 
data from three other regions (MP, Goa, and Orissa) are from this study. 
** Mutated amino acids are shown in boldface type. 
region separately, except A&N, where quadruple DHFR mu-
tations were predominant (Fig. 4). Furthermore, the numbers 
off. vivax isolates with double DHFR mutations were greater 
than those of P. falciparum (P = 0.023) in A&N. Elsewhere, 
the frequencies of double DHFR mutations for both the spe-
cies were almost same (P > 0.05), except for MP (P = 0.001). 
Interestingly, the quadruple DHFR mutations were observed 
in P. vivax but not in P. falciparum isolates from Assam (Fig. 4). 
all the seven regions of the country. Certain alleles were rare 
and rceJon specific, while others were present in more than one 
region ^Table 2). 
Analrsis of PFDHFR mutations. Previously, we described 
ihe PFDHFR mutations among 117 P. falciparum isolates from 
ihree regions of India (UP, Assam, and A&N) collected during 
2003 and 2004 (2). Here, we describe the PFDHFR mutations 
among 73 additional isolates collected from three other areas 
of the country (MP, Goa, and Orissa) during the same period 
(Table 3). Isolates from all three additional areas showed a 
predominance of the double PFDHFR mutations (Table 3), 
similar to the isolates from UP and Assam (2). Quadruple 
PFDHFR mutations from A&N reported previously (2) were 
not observed in any of the isolates, while triple PFDHFR 
mutations were present in Orissa (Table 3). 
Relationship between PVDHFR and PFDHFR mutations. P. 
falcipanim and P. vivax infections occur in all the seven study 
areas wliere we have analyzed the PVDHFR mutations (Table 
1). We have already described PFDHFR mutations among 117 
P. falciparum isolates from UP, Assam, and A&N (2), while the 
remaining 73 isolates from MP (n = 24), Goa (n = 22), and 
Orissa {n = 27) were sequenced here (Table 3). Therefore, we 
were able to analyze the DHFR mutations of P. falciparum 
(190 isolates) and P. vivax (177 isolates) combined together 
from these areas, except TN. As shown in Fig. 3 and as con-
firmed by the chi-square test, there was a specific trend of 
DHFR mutations across the P. falciparum and P. vivax groups 
iP = 0.0001). Nevertheless, the frequency of the wild-type 
PVDHFR genotype was significantly higher than that of the 
PFDHFR genotype [P = 0.0001) among all the isolates com-
bined together (Fig. 3) as well as in each region (Fig. 4). The 
numbers of isolates containing double DHFR mutations for 
each species wiere higher than the numbers of isolates with 
single, triple, or quadruple DHFR mutations among all the 
isolates combined together (Fig. 3) as well as isolates of each 
DISCUSSION 
Antifolate drugs are commonly used for the treatment of 
falciparum malaria. According to the National Drug Policy of 
India, chloroquine-resistant uncomplicated falciparum malaria 
cases should be treated with SP. In those regions of India 
where chloroquine resistance has reached a very high level, SP 
is the first line of antimalarial drug, except for a few primary 
health centers, where artesunate-based combined therapy has 
recently been introduced as an alternative treatment. If P. 
falciparum and P. vivax species coexist in the region, both of 
them are at risk of being exposed to the antifolate drugs, as 
they have common target en2ymes (7, 8). We found here that 
the antifolate drug pyrimethamine was also affecting the P. 
vivax parasite, as PVDHFR mutations were observed among 
isolates of all seven regions (Table 1). This may be due to the 
fact that both of these species coexist together in these regions. 
70^ 
apidHi{n. igo) 
Bp«'JWr(n« 177) 
WiW SingI* Deubl* Tripis 
Nutnbar of DHFR mutatloni 
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CT 
FIG. 3. Mutation patterns of P. vivax and P. falciparum DHFR 
enzyme sequences among total Indian isolates. The chi-square test was 
applied to assess the DHFR mutation trends across the species. 
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• pHWr(n-39) 
B(Mdh(r(n>38) 
Wild Slngla Ooubl* Tripl* 
Number of DHFR mutations 
Quadrupto 
Wild S i n ^ Double Triple Quadruple 
Numb«rofDHFR mutations 
B Madtiya Pradesh 
IOOT 
c 
o 
•3 
u 
£ 
• pMMr(n.38) 
a |MMr(n-24) 
SintJto Ooubl* Triple Quadruple 
Number of DHFR mutations 
Wild Single Double Triple Quadruple 
Number of DHFR mutations 
Goo Andanian & Nicobor 
100 
c 
• pldhlr(n>«0) 
apbdMr(n>3C4 
Wild Single Double T i ^ Quadrmie 
Number of DHFR mutations 
WHd Quadruple Single Doubia Tiiple 
Number Of DHFR mutations 
FIG. 4. Mutation patterns of P. vivax and P. falciparum DHFR enzyme sequences among the regional isolates. The PFDHFR data for UP, 
Assam, and A&N are derived from our previous studies (2). The chi-square test was applied to assess DHFR mutation rates among the groups. 
and chloroquine-resistant falciparum malaria is treated with 
SP (17). Exposure of P. vivax to SP can occur in these areas for 
several reasons. First, there could be a situation where the 
clinician prescribes the antimalarial drug based on clinical 
grounds but lacks the opportunity of immediate diagnosis, and 
the inaccurate diagnosis of the parasite species also leads to a 
similar situation. Second, economic issues can also lead to the 
treatment of P. vivax malaria with SP because it is cost-effec-
tive, easily available, and simple to administer due to its single-
do.se treatment regimen. Third, mixed P. falciparum and P. 
vivax infections may also be a reason for such a situation. 
Mixed infections are quite common in India despite the fact 
that there are separate transmission peaks for each species 
(19). This may be due to the fact that there is a window period 
that overlaps between the peaks and provides a congenial 
enviroi^mental condition for the transmission of both the spe-
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cies. Indeed, 26% of our malaria-infected blood samples from 
A&N showed mixed P. falciparum and P. vivax infections when 
detected by species-specific PCR for 18S rRNA gene se-
quences (data not shown). 
There was a regional variation in the PVDHFR mutation 
rates (Table 1). A similar regional variation in the PVDHFR 
mutations was also described previously by Kaur et al. (14). 
Rates of PVDHFR mutations reported from Chennai and Goa 
were similar to that of our data. However, the same group 
simultaneously reported a higher rate of PVDHFR mutations 
from Chennai (22) using a different methodology, i.e., PCR-
restriction fragment length polymorphism, which could not be 
as accurate as sequencing. Our data from Cuttack and Car 
Nicobar (Table 1) could not be compared with the data re-
ported previously by Kaur et al. (14) due to differences in 
sample sizes; for example, they analyzed only one isolate from 
Car Nicobar. Furthermore, we describe here PVDHFR muta-
tions from additional regions of India, i.e., Aligarh (UP), Ka-
mrup (Assam), and Panna (MP), and we also report here the 
prevalence of quadruple PVDHFR mutations in A&N and 
Assam that could be highly resistant to SP (9-12). Imwong et 
al. (11) also analyzed a few Indian isolates (n = 16) and found 
double PVDHFR mutations in 19% of them, but the origin of 
these isolates is not known. Similar to the data reported pre-
viously by Kaur et al. (14), we also did not find any mutation at 
13, 33, and 173 codons of the pvdhfr gene among Indian iso-
lates. However, we did not find any isolate with PVDHFR 
mutations at codons 37,109,131,159,171, and 188, which were 
considered novel by Kaur et al. (14). This discrepancy could 
arise due to different approaches used for sequencing, as Kaur 
et al. cloned the PCR products and then sequenced them, 
whereas we employed direct sequencing of the PCR products. 
These novel mutations have also not been reported from any 
other country by other workers in the field. Kaur et al. (14) 
reported PVDHFR mutation rates (29.75%; n = 121) for 
their isolates that were lower than those of the present study 
(57.06%; n = 177). The reason for this discrepancy may be the 
sample distribution, since the majority of their isolates, i.e., 96 
of 121 (79.34%), were obtained from Northern India, where 
wild-type PVDHFR predominates. 
It seems that there is a selective pressure (positive natural 
selection) on the pvdhfr gene leading to the increased fre-
quency of some of the alleles (Table 1,Table 2). However, the 
selective sweep of any particular allele cannot be suggested at 
this time point, since the flanking neutral markers for each of 
the mutant PFDHFR alleles are not yet fixed in the popula-
tion. This is because we have observed an enormous hetero-
geneity in these markers for each PVDHFR mutant allele 
among the isolates (M. T. Alam et al., unpublished data). 
Regional variations in the PVDHFR mutation rate observed 
here (Table 1) w a e similar to those for PFDHFR reported 
previously (2) and in Fig. 4. Since PFDHFR mutation data 
were available from these regions (except TN), we analyzed 
them along with PVDHFR mutations to as.sess the cross-spe-
cies impact of the drug. Interestingly, the PVDHFR mutation 
pattern was similar to that of the PFDHFR mutation pattern 
among the isolates (Fig. 3). There was a specific trend in 
DHFR mutations across the species. Isolates from each region 
also followed similar PVDHFR and PFDHFR mutation pat-
terns (Fig. 4). Similar DHFR mutation trends across species 
indicate that SP treatment of P. falciparum patients also af-
fected the P. vivax parasite population. 
Although we have observed similar DHFR mutation pat-
terns for both the species, there was a significant difference in 
the rate of DHFR mutations between P. vivax and P. falcipa-
rum. The overall DHFR mutation rate for P. vivax was signif-
icantly lower than that for P. falciparum (Fig. 3). Considering 
the fact that SP is used for P. falciparum malaria treatment and 
not for P. vivax, the latter parasite expectedly showed the lower 
rate of DHFR mutations among all these regions of the coun-
try. However, the frequency of PVDHFR mutations was higher 
in the P. /a/cjpamm-dominated areas and lower in the P. vivax-
dominated areas except Goa and TN (Table 1). SP resistance 
also varies in these regions, and it is higher in the P. falciparum-
dominated areas due to its expectedly higher usage (1-3, 17). 
Among the mainland isolates, the quadruple PVDHFR mu-
tations were observed only in Assam, where the SP pressure 
was higher since it is the first-line drug to treat falciparum 
malaria in this area (17). Therefore, it seems that the rate of 
PVDHFR mutations increased in P. /a/ciporum-dominated 
areas, which had higher usage of SP, and vice versa. Sur-
prisingly, so far, no P. falciparum i-solate from Assam has 
been found to contain the quadruple PFDHFR mutations as 
seen in A&N (2). Indeed, we have not detected any quadru-
ple PFDHFR mutations among the mainland isolates so far 
(1, 2). These results indicate that the P. falciparum strains 
from A&N are probably different from those from mainland 
India and therefore contain quadruple DHFR mutations 
similar to those of Southeast Asian strains, or quadruple 
mutations in PVDHFR arise faster than those in PFDHFR. 
This requires further investigations. 
It seems from our results that the antifolates used for P. 
falciparum treatment are also affecting P. vivax mutations. This 
warrants the careful usage of antifolates in order to check the 
development of cross-species resistance. 
ACKNOWLEDGMENTS 
Financial support for the work came from the Department of Bio-
technology (Government of India) and the Indian Council of Medical 
Research. M.T.A. and P.K.B. acknowledge the Council of Scientific 
and Industrial Research and University Grants Commission for Senior 
Research Fellowships, respectively. H.B. received a Junior Research 
Fellowship from the Indian Council of Medical Research. 
We are grateful to S. N. Dwivedi for statistical analysis of the data 
and M. R. Ranjit and Sumiti Vinayak for help and discussions. We also 
acknowledge facilities of the Biotechnology Information System (BTIS). 
REFERENCES 
1. Ahmed, A., D. Bararia, S. Vinayak, M. Yameen, S. Biswas, V. D«», A. Kumar, 
M. A. AnsMiri, and V. D. Sharma. 2()(M. Plasmodium fakipamm Isolates In 
India exhibit u progressive increase in mutations associated with sulfadoxlne 
pyrimethamine resistance. Antimicrob, Agents Chemother. 48:879-889. 
2. Ahmed, A., M. K. Das, V. Dev, M. A. Saifi, W^jihullah, and Y. D. Sharma. 
2006. Quadruple mutations in dihydrofolate reductase of nasmodium fal-
ciparum isolates from Car NIcbhar Island, India. Antimicrob. Agents Che-
mother. 50:1546-1549. 
3. Ahmed, A., V. Lumb, M. K. Das, V. Dev, W^jihullah, and Y. D. Sharma. 
2(X)6. Prevalence of mutations associated with higher levels of sulfadoxine-
pyrimethamine resistance in Plasmodium falciparum Isolates from Car Nico-
bar and Assam, India. Antimicrob. Agents Chemother. 50:3934-3938. 
4. Brega, S., F. de Monbrison, C. Severini, R. Udomsangpetch, I. Sulanio, P. 
Ruckert, F. Peyron, and S. PIcot. 2004. Real-time PCR for dihydrofolate 
reductase gene single-nucleotide polymorphisms in Plasmodium max iso-
lates. Antimicrob. Agents Chemother. 48!2581-2587. 
5. de Pecoulas, P. E., R. Tahar, P. Yi, K. H. Thai, and I^ K. Baseo. 2004. 
Genetic variation of the dihydrofolate reductase gene In Plasmodium vivax in 
Snoul, northeastern Cambodia. Acta Trop. 92:1-6. 
O 
O 
I 
I 
0) 
u 
3 
b (3 
IT 
•< 
O 
w (D 
•g. 
OD 
3 
(S 
o 
3 
V O L . 5 1 , 2007 ANTIFOLATE RESISTANCE IN / ' k/MA" A N D /' IALCIPARUM 863 
h it PeoMlas, P. E , L. K. Basco, R. Tahar, T. Oualai. and A. Mazabraund. 
1998 Analysis of the Plasmodium vtvax dihydrofolaie reduttase thymidyldle 
^nthas< gene sequence Gene 211:177-185 
7. dc Petoalas, P. E , R. Tahar, T. Ouatas, A. Mazabraud, and L. K. Basco. 
1998 Sequence variations in the Plasmodium mux dihydrofolate reductase 
thymidybte synthase gene and their relationship with pyrimethamine resus-
tance Mol Biochem Parasitol 92:265-273 
£. Gregsoa, A., aad C V. Ptom. 2IX)S Mechanism of resistance of malaria 
parasites to anuMates Pharmacol Rev 57:117-145 
« HastiOfs, M. D.. J. D. Magairt, M. J. Bangs, P. A. ZimmennaD, i. C Reeder, 
J. K. Baird, and C H. SiMej. 200S. Novel Plasmodium wrar dhfr alleles from 
the Indonesian Archipelago and Papua New Guinea, associauon with py-
nmelhamine resBlance determined by a Sacchammyces cemistae expression 
system. Antimicnib Agents Chemother 49:733-740 
in. HasUags, M. D.. K. M. Porter, J. D. Magnire, L Snsanti, W. Kania, M. J. 
Bangs, C H. SiMqr, and J. K. Baird. 2004. Dihydrofolate reductase muta-
tions in PlasmoiStun vivax from Indonesia and therapeutic response to sul-
fadoxiiK plus pyiimelhamine J Infect Dis 189:744-750 
II. ImwoDC M., S. Pakrittakayamec, S. Looartesuwaa, G. Pasvol, J. Poirricz, 
N. J. White, aad G. Snonnoo. 2001 Association of genetic mutations in 
Pfasmoiliiim vivxu dhfr with resistance to sulfadoxine-pyrimethaminc geo-
graphical and ciuiical correlates Antimicrob Agents Chemother 45:M22-
3127 
IZ. Imwoag, M., S. Paltnltayakamcc, L. Renia, F. Leionmeur, J. P. Charlieu, I) 
LeartsakulpanicK S. Looarccsuwan, N. J. White, and G. Snounou. 2U01 
\ovel point mutations in the dihydrofolate reductase gene of Plasmodium 
wvor kvidcnce for sequential selection by drug pressure Antimicrob 
Agents Chemother 47:1514-1521 
Jalah. R., R. Sarin, N. Sud, M. T. Alam, N. PanUi, T. K. Dash, and Y. D. 
Sharma. 2005 Identification, expression, localization and serological char 
acierization of a tiyptophan-nch antigen from the human malaria parasite 
Plasinodmm iiiur Mol Biochem Para.Mtol 141-158-169 
ICaur, S., S. K. Pnu>pali. K. Kaiyanaraman, A. Mohmmed. H. Joshi, and 
V. S. Chauhan. 20U6 fiasniodiiim vivai dihydrofolate reductase point mu-
tations from the Indian subcontinent Acta Trop 97:174-180 
15 Leartsakulpanidi, V., M. Imwong, S. Poknttayaliamee, N. J. White, G. 
(3 
U 
Snounou, W. Sirawarapom, and Y. Yuthavong. 2UU2 Molecular character-
ization of dihydrofolate reductase in relation to aniilolate resistance in 
Plasmodium vivax Mol Biochem Parasitol 119-63-73 
16 Na, B. K., H. W. Lee, S. V. Moon, T. S. In, K. Un, M Maung, G. T. Chung, 
J. K. Lee, T. S. Kim, and Y. Kong. 2(X)5 Genetic variations of the dihydro-
folate reductase gene of Plasmodium vivax in Mandalay Division, Myanmar 
Parasitol Res 96:321-325 
17 Sharma, V. P. 199*) Current scenario of malaria in India Parasitologia 
41:349-353 
18 Schunk, M., W. P. Kumma, I. B. Miranda, M. E. Osman, S. Roewer, A. 
Alano, T. Loscher, U. Bienzic, and F, P, Mockenhaupt 20U6 High preva-
lence of drug-resistance mutations in Plasmodium falciparum and Plasmo-
dium vtvax in Southern Ethiopia. Malar i 5:54-59 
19 Singh, N., S. S. Mishra, M. P. Singh, and V. P. Sharma. 2000 Seasonality of 
Plasmodium vivax and P falciparum m tribal villages in central India (1987' 
1995) Ann Trop Med Parasitol 44:101-112 
20 Tahar, R., P. E. de Pecouias, L. K. Basco, M. Chiadmi, and A. Mazabraud. 
2001 Kinetic properties of dihydrofolate reductase from wild-type and 
mutant Plasmodium vi\ax expres.sed in EsUienthia coli Mol Biochem 
Parasitol 113:241-249 
21 Tjiira, ¥.., J. Baker, S. Suprianto, Q. Cheng, and N. M. Anstcy. 2002 
Ihetapeutit efficacies ot artesunaie-sulfadoxine pyrimethamine and 
chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies 
relationship to Plasmodium \nax dhfr mutations Antimicrob Agents 
Chemother 46:3947-3953 
22 Valecha, N., H. Joshi, A. Eapen, J. Ravindenin, A Kumar, S. K. Pr^apati, 
and P Ringwald. 2006 Therapeutic efticacy of chloroquine in Plasmodium 
vivax from areas with different epidemiological patterns in India and their 
Pid/i/r gene mutation pattern Trans R Soc Trop Med Hyg I00-831-837 
23 Wang, P., C. S. Lee, R. Bayoumi, A. Djimde, O. Doumbo, G. Swedberg, U D. 
Das, H. Mshmda, M. Tanner, W. M. Walkins, P. F. G. Sims, and J. E. Hyde. 
1997 Resistance to antifolate in Plasmodium falciparum monitored by se-
quence analysis of dihydropteroate synthetase and dihydrofolate reductase 
alleles in a larger number of field samples of diverse origin Mol Biochem 
Parasitol 89:161-177 
O 
O 
« 
O 
CD 
a 
o 
a 
o 
3 
m 
0) 
o 
m 
U) 
o 
a 
cr 
>< 
o 
W 
3 
cr 
(D 
o o 
